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Summary 
Pulmonary hypertension is a disease characterised by progressive pulmonary 
vascular remodelling and obliteration with consequent development of right 
heart failure and ultimately death. First described many decades ago with a 
median survival of less than 3 years and no available treatments, the 
development of disease specific pulmonary vasodilator therapy has led to only 
modest improvements in survival and it remains an almost universally fatal 
disease.  
One of the key symptoms of pulmonary hypertension is exercise intolerance, 
primarily a consequence of the underlying right ventricular failure and an 
inability to augment stroke volume on exercise. The gold standard diagnostic 
test is right heart catheterisation but this is unattractive as a tool for ongoing 
monitoring as it is invasive and not without risk, albeit that risk is small. As a 
result most monitoring of disease progression and of treatment response is 
carried out using surrogate markers, often exercise based such as the 6 minute 
walk test.  
Increasing attention is focused on the role of exercise both in that monitoring of 
patients and also in helping to understand better the pathophysiology. The work 
presented in this thesis therefore aimed to explore novel exercise derived 
variables and noninvasive haemodynamic measurement as tools to improve our 
understanding of the disease limitation, to enhance our monitoring of treatment 
response and to give additional prognostic information. 
In Chapter 3 the role of peripheral muscle oxygen extraction and exercise 
limitation was explored by performing right heart catheterisation on exercise 
with measurement of mixed venous oxygen saturation. This demonstrated that 
patients with pulmonary hypertension demonstrate no evidence of impaired 
oxygen extraction and that they appear to extract at least as much oxygen on 
exercise as healthy individuals have been shown to in other studies. This 
indicates that impairment of oxygen extraction is not a cause of exercise 
limitation in pulmonary hypertension. 
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Chapter 4 describes a series of studies evaluating the potential role of the 
oxygen uptake efficiency slope in pulmonary hypertension. This variable derived 
from the oxygen consumption and ventilation across an incremental 
cardiopulmonary exercise test has demonstrated promise as a potential 
submaximal measure of exercise performance and predictor of survival in left 
heart failure. The studies conducted demonstrated that this variable is a 
measure of peak exercise performance in pulmonary hypertension, that it can be 
measure on submaximal levels of exercise and that it predicts survival in 
patients with Group 1 and Group 4 disease. 
The studies described in Chapter 5 investigated the rates of recovery of heart 
rate and oxygen consumption after exercise and found that both could predict 
survival. In particular the rate of recovery of heart rate after exercise was 
demonstrated to be a strong predictor of survival on multivariate analysis, thus 
providing a further method of assessing prognosis with exercise. 
Finally the ability of noninvasive measures of stroke volume to predict outcome 
was explored in the studies detailed in Chapter 6. The underlying haemodynamic 
abnormalities are not assessed when surrogate measures such as exercise testing 
are employed in patient follow up. Standard practice is to review patients 3 to 4 
months after any change in treatment and to assess them using these surrogate 
measures. Acute haemodynamic changes are able to be detected invasively 
immediately after administration of pulmonary vasodilator therapy. This study 
therefore investigated the ability of two noninvasive methods of measuring 
stroke volume, inert gas rebreathing and cardiac MRI, to detect treatment 
response after only 2 weeks and assess how this related to functional 
improvement at the standard 4 months. The study found that haemodynamic 
changes were able to be detected at 2 weeks and these appeared to relate to 
changes in 6 minute walk distance at the same time point but did not appear to 
relate to 6 minute walk distance at 4 months. This study however did not reach 
its recruitment target and therefore further work is needed in this area. 
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1 Introduction 
  
17 
 
1.1 Definition and background 
Pulmonary hypertension (PH) is defined as a resting mean pulmonary artery 
pressure (mPAP) ≥ 25mmHg1, 2. Although the upper limit of normal of mPAP is 
20mmHg3, the use of 25mmHg as the cut-off value to define PH has been used 
since the first World Symposium on Pulmonary Hypertension (WSPH) in 1973 and 
is now well established in both clinical guidelines1, 4, 5 and epidemiological6-8 and 
clinical trials9-12. The term PH refers not to a single disease but to this elevation 
in pulmonary artery pressure (PAP) when seen in association with a wide group 
of conditions, some of which affect the pulmonary vasculature directly and 
others which affect it indirectly. Key to the pathophysiology of PH is the 
development of progressive right ventricular (RV) failure which causes symptoms 
including increasing breathlessness, peripheral oedema and exertional 
presyncope and syncope. 
Ultimately, unchecked PH results in premature death. Prior to the advent of 
disease specific pharmacological therapy, survival with PH was very poor. In 
1991 in the United States of America a large multicentre registry study of 194 
patients diagnosed with what was then known as primary PH demonstrated a 
median survival of only 2.8 years with 5 year survival of 34%13. Since that work 
was published an increasing number of targeted therapeutic options have proven 
successful in clinical trials and thereafter been incorporated into routine patient 
management with a resultant increase in survival however PH remains associated 
with significant morbidity and mortality. Data from the 2015 United Kingdom 
National Audit of Pulmonary Hypertension indicates that for a patient population 
similar to that described in the 1991 registry study outlined above, median 
survival remains poor at 4 years and 104 days despite the advances made in 
treatment14. 
This chapter will describe the background to and rationale for the work 
presented in this thesis. It explains the current clinical classification of PH, the 
pathophysiology of the disease process and the diagnostic and management 
strategies employed in the management of patients with PH. The 
pathophysiology of exercise limitation and the role of exercise testing in PH is 
described and consideration is given to noninvasive methods of measuring 
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haemodynamic variables in PH. The aims and hypotheses of the work presented 
in this thesis are then defined. 
1.2 Clinical classification of pulmonary hypertension 
An accepted structure for the clinical classification of PH was first agreed in 
1998 at the second WSPH in Evian, France15, grouping subtypes of PH by common 
features of pathology, clinical and haemodynamic features, and treatment. This 
classification has been modified over the subsequent WSPH meetings in Venice, 
Italy in 200316, Dana Point, California in 200817 and most recently in Nice, France 
in 201318, although the overall structure has remained. The Dana Point 
classification was the contemporary classification at the time the studies 
described in this thesis were carried out and this is described in Table 1.1. 
Although some changes were made at the 2013 WSPH18 none of these would have 
affected the inclusion of the patients who participated in the studies. Patients 
with group 1 or group 4 PH were eligible for participation in the studies reported 
in this thesis while those with a diagnosis of group 2, 3 or 5 PH were excluded.  
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2008 Dana Point Clinical classification of PH 
Group 1 Pulmonary arterial hypertension 
 1.1 Idiopathic PH 
 1.2 Heritable 
  1.2.1 BMPR2 
  1.2.2 
ALK1, endoglin (with or without hereditary 
haemorrhagic telangiectasia) 
  1.2.3 Unknown 
 1.3 Drug- and toxin-induced 
 1.4 Associated with 
  1.4.1 Connective tissue diseases 
  1.4.2 HIV infection 
  1.4.3 Portal hypertension 
  1.4.4 Congenital heart diseases 
  1.4.5 Schistosomiasis 
  1.4.6 Chronic haemolytic anaemia 
 1.5 Persistent pulmonary hypertension of the newborn 
1’ 
Pulmonary veno-occlusive disease and/or pulmonary capillary 
haemangiomatosis 
Group 2 Pulmonary hypertension owing to left heart disease 
Group 3 Pulmonary hypertension owing to lung diseases and/or hypoxia 
Group 4 Chronic thromboembolic pulmonary hypertension 
Group 5 Pulmonary hypertension with unclear multifactorial mechanisms 
 
5.1 Haematological disorders: myeloproliferative disorders, 
splenectomy 
 
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans 
cell histiocytosis, lymphangioleiomyomatosis, 
neurofibromatosis, vasculitis 
 
5.3 Metabolic disorders: glycogen storage disease, Gaucher 
disease, thyroid disorders 
 
5.4 Others: tumoural obstruction, fibrosing mediastinitis, 
chronic renal failure on dialysis 
Table 1.1 2008 Dana Point clinical classification of pulmonary hypertension. PH: pulmonary 
hypertension; BMPR2: bone morphogenetic protein receptor type 2; ALK1: activin receptor-
like kinase type 1; HIV: human immunodeficiency virus. 
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1.3 Pathogenesis of pulmonary hypertension 
The healthy pulmonary circulation consists of thin walled blood vessels in a low 
pressure, high flow system19 with significant vascular reserve20. The pathogenesis 
of pulmonary arterial hypertension (PAH) is multifactorial and not yet fully 
understood21 but at its core consists of pulmonary vascular proliferation and 
remodelling, thrombosis and vasoconstriction causing a progressive rise in 
pulmonary vascular resistance (PVR) and consequent RV failure4, 19, 20. Primarily 
affecting vessels less than 500µm diameter the pathological changes seen in PAH 
include the development of smooth muscle in the wall of distal, usually 
nonmuscular, pulmonary arteries; neointima formation in which a layer 
consisting of extracellular matrix and myofibroblasts forms between the 
endothelium and the internal elastic lamina; and endothelial cell proliferation 
leading to the formation of complex vascular lesions known as plexiform 
lesions20, 22. Pulmonary veins are generally felt to be unaffected by the disease 
process in PAH although this is an area of current research interest21. 
Several cellular and molecular processes contribute to these pathological 
changes including upregulation of matrix metalloproteinases, disordered 
inflammation in favour of proinflammatory cytokines, a prothrombotic state 
leading to in situ thrombosis, induction of growth factors stimulating vascular 
remodelling such as vascular endothelial growth factor (VEGF), and endothelial 
dysfunction with a fall in production of endogenous vasodilators including nitric 
oxide (NO) and prostacyclin, and an increase in vasoconstrictor compounds such 
as endothelin 1 (ET-1) and thromboxane A219-21, 23, 24. 
The pathogenesis of group 4 PH, i.e. chronic thromboembolic pulmonary 
hypertension (CTEPH) has a degree of overlap with that of group 1 PAH. 
Although as many as 50% of patients diagnosed with CTEPH have no identifiable 
prior episode of venous thromboembolism (VTE) it is widely accepted that the 
initial event in the pathogenesis is an episode of pulmonary embolism (PE)25. For 
reasons that have yet to be fully elucidated, there is aberrant thrombus 
resolution, resulting in pulmonary vascular narrowing and obliteration with the 
development of organised thrombus and vascular bands and webs4, 26, 27. This 
vascular obstruction diverts blood flow through unaffected pulmonary arteries, 
triggering the development of a similar vasculopathy to that seen in PAH with 
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increased shear stress, cytokine release and activation of proinflammatory 
pathways, and increased levels of ET-1, even in the absence of any further 
episode of PE25, 28, 29.  
While one prospective follow up single centre study suggested that CTEPH may 
develop in up to 3.8% of patients after an episode of PTE30 the true rate is 
believed to be lower with international guidelines suggesting a rate of 0.5 – 2%4. 
Other factors associated with an increased risk of developing CTEPH include 
previous splenectomy, the presence of a ventriculo-atrial shunt for 
hydrocephalus and a history of chronic inflammatory disease25, 26. Although 
thrombophilia per se has not been associated with the development of CTEPH 
studies have demonstrated increased levels of factor VIII, von Willebrand factor 
and antiphospholipid antibody26. 
 
1.4 Diagnosis of pulmonary hypertension 
Given the many possible causes for PH as described in Table 1.1 and that the 
treatment for each PH group is different, securing an accurate diagnosis is 
essential. Internationally recognised guidelines describing how best to achieve 
this have been published and were followed as standard practice in the Scottish 
Pulmonary Vascular Unit at the time of the studies described in this thesis. 
1.4.1 Clinical presentation 
Patients most commonly present with nonspecific symptoms of progressive 
exertional breathlessness and fatigue, having been symptomatic usually for 
several months or years before diagnosis, with a mean time from symptom onset 
to diagnosis in an early registry study of 2 years31. The gradual onset contributes 
to the long time to diagnosis as initial symptoms may be dismissed as a lack of 
fitness32. As the disease progresses and RV failure develops other symptoms of 
chest pain, peripheral oedema, presyncope and syncope may develop, with 
symptoms at rest indicating advanced disease4. There may be a history of illness 
with one of the conditions associated with Group I PH, e.g. connective tissue 
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disease, HIV infection or liver disease, or there may be a positive family history 
in a small number of cases.  
On examination the most common and potentially only feature in the earlier 
stages of the disease may be a loud second heart sound in the pulmonary region. 
A pansystolic murmur at the left lower sternal edge consistent with tricuspid 
regurgitation may be heard and in the presence of RV failure a right ventricular 
heave may be felt in the left parasternal area32. On examination of the jugular 
veins there may be a prominent “a” wave as the right atrium contracts in the 
presence of a non-compliant RV and “v” wave as a consequence of tricuspid 
regurgitation. With the development of RV failure, the jugular venous pressure 
(JVP) will rise and peripheral oedema will develop, detectable in the legs and 
possibly also the sacrum and, in the form of ascites, in the abdomen. A third 
heart sound may be heard in advanced disease and central cyanosis develops. 
Examination of the lungs is usually unremarkable. 
Clinical examination may reveal signs suggestive of an underlying cause of 
secondary PH, either in the form of left heart disease suggesting possible Group 
2 disease or lung disease in keeping with a possible diagnosis of Group 3 disease. 
There may be stigmata of liver disease such as spider naevi, hepatomegaly or 
gynaecomastia, or clinical evidence of connective tissue disease, e.g. 
telangiectasia, Raynaud’s, skin changes in the face and hands or digital 
ulceration.  
1.4.2 Initial investigations 
In PH the electrocardiogram (ECG) will frequently reveal evidence of RV 
hypertrophy and strain31 however a normal ECG cannot be used to exclude the 
disease as it has insufficient sensitivity and specificity (55% and 70% 
respectively)4. Most patients with PH will be sinus rhythm but the development 
of atrial fibrillation or other supraventricular tachycardias will in the vast 
majority of cases precipitate clinical deterioration and worsening right heart 
failure33, and such an event may trigger the initial assessment.  
The chest x-ray is abnormal in as many as 90% of patients at diagnosis31. It may 
demonstrate enlarged central pulmonary arteries with “pruning” of the more 
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peripheral vessels and in more advanced disease may show evidence of RV and 
right atrial (RA) enlargement. It may in addition suggest the presence of lung 
disease or, in the presence of cardiomegaly, pulmonary oedema and/or bilateral 
pleural effusions, left heart disease. 
1.4.3 Echocardiogram findings 
The standard screening test for PH is the echocardiogram, used to provide an 
estimate of PA pressure, and to assess left ventricular (LV) and RV function4. 
Using the modified Bernoulli equation the PA systolic pressure (PASP) can be 
estimated as 
𝑃𝐴𝑆𝑃 = 𝑇𝑅𝑃𝐺 + 𝑅𝐴𝑃 
 where  PASP =  pulmonary artery systolic pressure  
   TRPG =  tricuspid regurgitation pressure gradient 
   RAP =  right atrial pressure, estimated on the basis of 
     the diameter and variation with respiration of 
     the inferior vena cava 
and 
𝑇𝑅𝑃𝐺 = 4 ⋅ (𝑇𝑅𝑉)2 
 where  TRV = peak velocity of the tricuspid regurgitant jet34. 
The estimated PASP measure at echocardiogram can in theory be used to 
estimate the mPAP but it is not sufficiently accurate for this to be relied on in 
clinical practice due to the frequency of overestimation or underestimation of 
the PASP35. It is however useful as a screening tool except in the mildest cases of 
PH4. 
The echocardiogram provides information on left ventricular function which may 
suggest pulmonary venous hypertension (PVH), i.e. Group 2 disease as the cause 
of PH. Evidence of septal or other congenital defects may be seen and the use of 
bubble contrast may indicate the presence of a right to left shunt. 
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In addition to the diagnostic information provided, the echocardiogram also 
provides prognostic information. The tricuspid annular plane systolic excursion 
(TAPSE) is a measure of apex-to-base RV shortening in systole and correlates 
with RV ejection fraction36. It has also been shown to be a significant predictor 
of survival in PAH37, 38. Right atrial size and the presence and severity of 
pericardial effusion have also been shown to associate with disease severity and 
to predict survival39, 40. 
1.4.4 Further investigations 
If the clinical assessment and echocardiogram are suggestive of PH with no 
evidence of significant lung or left heart disease then further investigation is 
warranted. It is at this point that patients would usually be referred to the 
Scottish Pulmonary Vascular Unit (SPVU) (see Chapter 2.1) for more detailed 
assessment. The purpose of these further investigations is to confirm the 
pulmonary vascular haemodynamic measurements and to elucidate the cause if 
PH is confirmed. 
1.4.4.1 Blood investigation 
Routine haematological and biochemical blood investigations including 
assessment of liver and thyroid function, an autoimmune screen looking for 
evidence to suggest a diagnosis of connective tissue disease, and HIV and 
hepatitis C screening serology are checked in all patients. Although 
thrombophilia screening is recommended4, local guidelines are that this should 
not be checked unless there is a clear family history as in the event that a 
diagnosis of CTEPH is made, lifelong anticoagulation will be required regardless 
of the presence or absence of an underlying clotting disorder.  
1.4.4.2 Tests of respiratory function 
Pulmonary function tests (PFTs) are performed in all patients suspected of 
having PH. The primary reason for conducting PFTs is to look for evidence of 
interstitial lung disease or airways disease and therefore suggest a possible 
diagnosis of Group 3 PH. However it also provides useful information in patients 
without lung disease as a cause of PH. In cases of PAH, spirometry is usually 
normal or close to normal but the diffusing capacity of the lungs for carbon 
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monoxide (DLCO) may be markedly reduced and correlate inversely with 
survival41, 42. Although a severely reduced DLCO can occur in patients with 
idiopathic pulmonary arterial hypertension (IPAH)42, such a marked reduction 
should raise the possibility of connective tissue disease associated PH 
(CTDPH)43or pulmonary veno-occlusive disease (PVOD)44 in the absence of left 
ventricular lung disease or lung disease. 
Consideration should be given to whether obstructive sleep apnoea or obesity 
hypoventilation are present and if symptoms are suggestive, screening with 
overnight transcutaneous monitoring or polysomnography can be undertaken4. 
1.4.4.3 Ventilation/perfusion scanning 
Ventilation/perfusion (V/Q) scanning should be performed in all patients with 
suspected PH to screen for possible CTEPH. Although possessing similar 
specificity, the V/Q scan has considerably greater sensitivity for the detection of 
pulmonary thromboembolic disease than does multidetector computed 
tomography pulmonary angiography (CTPA) with sensitivity 96 - 97.4% for V/Q 
scanning compared with 51% for CTPA45. Specificity is over 90% for V/Q and 99% 
for CTPA. 
1.4.4.4 Cross sectional imaging 
Cross sectional imaging in the form of high resolution computed tomography 
(HRCT) scanning and CTPA are undertaken in all patients. The HRCT is optimised 
for assessment of the lung parenchyma and therefore is used to examine for 
evidence of lung disease which could be the cause of PH, i.e. Group 3 disease. 
However features of PVOD may be seen, namely septal lines and ground glass 
opacities in keeping with interstitial oedema46.  
CTPA may demonstrate dilatation of the main pulmonary artery (PA) and right 
sided cardiac chambers in all forms of PAH but of particular note are the findings 
seen in CTEPH. Bilateral pleural effusions and mediastinal lymphadenopathy may 
be seen in PVOD and in left heart disease. Although less sensitive than V/Q 
scanning CTPA can provide information on the structural abnormalities affecting 
the pulmonary vasculature. Complete obstruction, eccentric laminated 
thrombus, stenosis in the form of bands or webs, and other intimal irregularities 
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may be seen47. Peripheral wedge shaped opacities representing areas of previous 
pulmonary infarction and mosaic perfusion may also be seen. 
1.4.4.5 Cardiac magnetic resonance imaging 
Cardiac magnetic resonance imaging (MRI) provides a noninvasive mode of 
assessing RV structure and function and pulmonary vascular haemodynamics in 
the form of stroke volume (SV) and cardiac output (CO), and can add to the 
diagnostic assessment of patients with suspected PH, in terms of both the cause 
and the disease severity. Cardiac MRI is discussed in more detail in chapter 
1.8.1.  
1.4.4.6 Measurement of brain natriuretic peptide 
Cardiac wall stress stimulates the mycocardium to release atrial and brain 
natriuretic peptides. These molecules increase natriuresis and also vasodilation. 
In PH, most research into natriuretic peptides has focused on brain natriuretic 
peptide (BNP). The molecular precursor of BNP is proBNP. BNP is formed when 
the N-terminal of proBNP (NTproBNP) is cleaved from the larger molecule, 
producing BNP. Both BNP and NTproBNP can be quantified in blood and both 
have been shown to have prognostic significance. NTproBNP is more stable in 
blood and after sampling and has a longer half-life. As a consequence it is used 
in preference to BNP in the assessment of patients attending the SPVU. 
Work carried out in the SPVU demonstrated that NTproBNP at baseline 
correlated negatively with RV ejection fraction (RVEF) and was a highly sensitive 
and specific marker of RV systolic dysfunction (RVSD) 48. This relationship 
between NTproBNP and disease severity is now well established. Higher levels 
are associated with higher mortality49-51, increasing levels are associated with 
deteriorating RV systolic function52 and falling levels have been seen in patients 
with improved haemodynamics on treatment49.  
1.4.4.7 Assessment of functional capability 
With exercise limitation one of the key features of PH symptomatology, tests of 
exercise capacity have a role in the assessment of disease severity at baseline 
and on follow up. The most commonly used tests in PH re the 6 minute walk test 
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(6MWT) and the cardiopulmonary exercise test (CPET)4 and these are discussed 
in Chapter 1.7.3.  
The World Health Organisation Functional Class (WHO-FC) is a widely accepted 
method of stratifying patients with PH by the effect it has on their ability to 
perform activities. It is described in Chapter 2.2. Patients with poor WHO-FC 
have been demonstrated to have poorer survival than those in the best 
functional classes13. 
1.4.5 Right heart catheterisation 
To confirm the diagnosis all patients must undergo right heart catheterisation 
which remains the gold standard method of clarifying the presence of PH, 
quanitifying the severity of the haemodynamic impairment and testing the 
degree of vasoreactivity of the pulmonary circulation2, 4. RHC is performed and 
measurements made as described in Chapter 2.7.1. When conducted in 
experienced centres such as the SPVU the rate of complications of RHC is low. In 
one multicentre retrospective and prospective study evaluating serious adverse 
events (SAEs) related to RHC in patients with PH found a rate of SAEs of 1.1%, 
the most frequent of which related to the initial venous puncture, with cardiac 
arrhythmia and hypotension occurring less frequently53. The overall procedure 
related mortality in that series was 0.059%.  
The haemodynamic definition of different groups of PH is given in Table 1.2.  
Haemodynamic definitions of pulmonary hypertension 
Definition Haemodynamics PH Group 
Pulmonary hypertension mPAP ≥ 25 mmHg All 
Pre-capillary PH 
mPAP ≥ 25 mmHg 
PAWP ≤15 mmHg 
CO normal or reduced 
Group 1 
Group 3 
Group 4 
Group 5 
Post-capillary PH 
mPAP ≥ 25 mmHg 
PAWP > 15 mmHg 
CO normal or reduced 
Group 2 
Table 1.2 Haemodynamic definitions of pulmonary hypertension. mPAP: mean pulmonary 
artery pressure; PH: pulmonary hypertension; PAWP: pulmonary artery wedge pressure; 
CO: cardiac output. PH groups are as described in Table 1.1. 
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In some patients with suspected Group 2 PH, particularly those in whom LV 
diastolic dysfunction may be suspected on the basis of history and other 
investigations, a normal pulmonary artery wedge pressure (PAWP) may still be 
seen, suggesting a diagnosis of precapillary PH. In such cases of raised suspicion 
the PAWP may be “challenged”, either with a period of exercise on the cardiac 
catheterisation table or by giving a rapid fluid challenge of 0.9% saline and 
assessing for a disproportionate rise in the PAWP54.  
In cases of haemodynamically confirmed PAH, vasoreactivity testing should be 
undertaken4. In these patients an acute vasodilator is given following initial RHC 
measurements. As is the case in the SPVU, inhaled nitric oxide (NO) is the acute 
vasodilator used most often although intravenous epoprostenol may also be 
used. A positive response in defined as a reduction in mPAP of ≥ 10 mmHg to an 
absolute mPAP of ≤40 mmHg, with a stable or increased CO4, 55. The importance 
of this vasoreactivity testing is that patients who have a positive response are 
most likely to response to long term treatment with calcium channel blockers 
and have a better outlook than non-responders55, 56.  
1.4.6 Conventional pulmonary angiography 
In patients in whom a diagnosis of CTEPH is suspected, generally those patients 
with a suggestive V/Q scan and/or CTPA, conventional pulmonary angiography 
should be performed at the time of RHC4. This provides detailed imaging of the 
extent and distribution of vascular defects, confirming the diagnosis, and 
enables planning of the optimum therapeutic strategy.  
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1.5 Features of prognostic significance 
The various components of the assessment described in Chapter 1.4 should be 
taken together to give an overall view of prognosis. Those features which are of 
established prognostic significance are given in Table 1.3, adapted from 
McLauglin and McGoon, 200957 and Galié et al, 20094.  
Assessment of disease severity and prognosis 
Better prognosis 
Determinants of 
prognosis 
Worse prognosis 
No 
Clinical evidence of RV 
failure 
 
Slow 
Rate of symptom 
progression 
 
No Syncope  
I/II WHO-FC  
Longer, > 500m 6 minute walk distance Shorter, <300m 
Peak VO2 > 15ml/min/kg 
Cardiopulmonary 
exercise test 
Peak VO2 < 12ml/min/kg 
Normal/near-normal BNP/NTproBNP Very elevated and rising 
No pericardial effusion 
TAPSE > 2cm 
Echocardiographic 
findings 
Pericardial effusion 
TAPSE < 1.5cm 
RAP < 8mmHg and  
CI ≥ 2.5l/min/m2 
Haemodynamics 
RAP > 15mmHg or 
CI ≤ 2.0l/min/m2 
Table 1.3 Features associated with better or worse prognosis in patients with pulmonary 
arterial hypertension, adapted from McLaughlin and McGoon, 200957 and Galié et al, 20094. 
RV: right ventricular; WHO-FC: World Health Organisation Functional Class; BNP: brain 
natriuretic peptide; NTproBNP: N terminal proBNP; TAPSE: tricuspid annular plane systolic 
excursion; CI: cardiac index. 
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1.6 Treatment of pulmonary arterial hypertension 
1.6.1 General measures 
1.6.1.1 The role of anticoagulation 
There is a longstanding recommendation that patients with IPAH be 
therapeutically anticoagulated, originally with warfarin and more recently with 
novel oral anticoagulant agents. Post mortem examination of lung tissue from 
patients with IPAH and other studies in wider groups of PAH have demonstrated 
a high prevalence of thrombotic lesions58 and in retrospective studies found 
anticoagulation to be associated with significantly better survival compared to 
those patients who were not anticoagulated58. A more recent study analysing 
data from the Comparative, Prospective Registry of Newly Initiated Therapies for 
Pulmonary Hypertension (COMPERA) has confirmed the beneficial effect of 
anticoagulation in Group 1 PH but only in those patients with IPAH and no 
beneficial effect of treatment with anticoagulants was seen in patients with 
other types of PAH59. Clearly patients with CTEPH should have lifelong 
anticoagulation4. 
1.6.1.2 Diuretics 
Patients with progressive RV failure are prone to becoming fluid overloaded with 
increasing right heart pressure and the accumulation of peripheral oedema and 
in some cases ascites. There are no randomised controlled trials (RCTs) of 
diuretic use in patients with PH but the symptomatic benefits of diuresis are 
widely accepted4. 
1.6.1.3 Oxygen 
There is some evidence from the study of PH secondary to lung disease that 
administration of long term oxygen therapy can lead to improvements in the 
pulmonary vascular component of that disease process60. This and other 
evidence has been extrapolated to the management of PH and it is 
recommended that patients with a partial pressure of oxygen in arterial blood of 
less than 8 kPa receive oxygen at rates to maintain a level greater than 8kPA for 
at least 16 hours a day4. 
31 
 
1.6.2 Specific pulmonary vasodilator therapy 
1.6.2.1 Calcium channel blockers 
As described in Chapter 1.4.5, patients with IPAH who have a significant 
response to an acute pulmonary vasodilator trial should be treated with calcium 
channel blockers55, 56. Patients meeting this criterion and who are started on 
calcium channel blockers should be monitored closely and if there is poor 
evidence of efficacy then additional or alternative PH therapy should be 
instituted4, 61. 
1.6.2.2 Phosphodiesterase type 5 inhibitors 
Phosphodiesterase type 5 (PDE5) inhibitors are often used as first line therapy in 
Group 1 PH. PDE5 is expressed in high concentrations in the pulmonary 
vasculature. It enzymatically degrades cyclic guanosine monophosphate and 
inhibition of this causes vascular smooth muscle relaxation through the NO/cGMP 
pathway and thus cause vasodilation. It has been suggested from in vitro work 
that there may be an additional beneficial effect on pulmonary vascular 
remodelling by reducing proliferation62, 63. 
The beneficial effects of the PDE5 inhibitors sildenafil and tadalafil in PAH have 
been demonstrated in RCTs. SUPER-1 showed sildenafil to have a beneficial 
impact on exercise capacity, WHO-FC and haemodynamics compared with 
placebo10 while SUPER-2, the long term uncontrolled extension study which 
followed SUPER-1, demonstrated the drug to be generally well tolerated64. The 
PHIRST study of tadalafil showed that compared with placebo, tadalafil 
increased 6 minute walk distance (6MWD), even in patients already on treatment 
with bosentan (see Chapter 1.5.2.3), and also improved time to clinical 
worsening and quality of life measures65. In a similar manner to SUPER-2, a 
tadalafil long term uncontrolled extension study was conducted, PHIRST-2, 
demonstrating that tadalafil was well tolerated and that the improvements seen 
in 6MWD in PHIRST appeared to be maintained after one year of treatment66. 
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1.6.2.3 Endothelin receptor antagonists 
Endothelin-1 is a powerful vasoconstrictor released primarily from vascular 
endothelium and as described in Chapter 1.3 plays a role in the pathogenesis of 
PH. It binds to both ETA and ETB receptors in the vasculature. ETA receptors are 
found in vascular smooth muscle cells with ETB receptors located on both 
vascular smooth muscle cells and vascular endothelial cells. When ET-1 binds to 
receptors of either type, vasoconstriction occurs. ET-1 binding to ETB receptors 
on endothelial cells however stimulates clearance of ET-1, stimulation of NO 
release and stimulation of prostacyclin release67, thus promoting vasodilation. 
Endothelin receptor antagonists (ERAs) were developed to counteract this 
increased expression of ET-1 in PAH. Bosentan is an oral dual ETA and ETB 
receptor antagonist. Its beneficial effects on 6MWD, WHO-FC, haemodynamic 
measurements and time to clinical worsening were demonstrated across a series 
of placebo controlled trials including the BREATHE series of studies and the 
EARLY trial9, 68-70. Longitudinal observational data has demonstrated that 
bosentan is safe and the improvements seen appear to be sustained long term71 
with improved survival72. Approximately 10% of patients develop raised liver 
aminotransferases. Although this is reversible on stopping the drug, patients on 
treatment with bosentan should have monthly liver function test monitoring4, 61.  
A second ERA, ambrisentan, has been accepted for use in patients with PAH. It is 
a selective ETA receptor antagonist and its efficacy was first demonstrated in 
two concurrent randomised double blinded placebo controlled studies, ARIES-1 
and ARIES-273. These trials found that therapy with ambrisentan was associated 
with improvements in 6MWD, WHO-FC, time to clinical worsening and BNP. 
Although increases in liver aminotransferases were less frequent and less marked 
than with bosentan treatment, patients on therapy with ambrisentan should also 
have monthly liver function test monitoring. 
A third ERA has more recently been developed for use in PAH. Macitentan is a 
dual ETA and ETB receptor antagonist and has been demonstrated to improve 
morbidity and mortality in patients with PAH when compared with placebo in the 
SERAPHIN study74. It was not yet available for use at the time of the studies 
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described in this thesis. A further ERA, sitaxentan, was withdrawn in December 
2010 due to associated liver toxicity75-77.  
1.6.2.4 Prostanoids 
Prostacyclin is a potent endogenous vasodilator and is downregulated in PAH78. 
Synthetic analogues have therefore been developed for use in PAH. Epoprostenol 
is administered as a continuous intravenous infusion, usually via a Hickman line. 
No randomised double-blinded controlled trials of epoprostenol have been 
conducted but it has long been accepted as the treatment of choice, in 
combination with oral therapies, for patients with the most severe disease. 
Evidence of its benefit in PAH comes from unblinded randomised controlled 
trials demonstrating a sustained reduction in mPAP and improvements in 
exercise capacity and survival79-81. Flushing, headache, gastrointestinal upset 
and jaw pain may occur with increasing doses but the most severe complications 
come from the delivery system, including the possibility of pump failure and line 
infection or blockage. Due to the short half life of the drug there is a risk of 
rebound PH, potentially fatal, if the drug infusion is stopped or interrupted 
suddenly4. 
Another prostacyclin analogue, treprostinil, can be given either intravenously or 
subcutaneously, although inhaled and oral preparations have also been 
produced. It is not used routinely in the care of patients attending the SPVU but 
has been shown to cause a significant improvement in 6MWD, WHO-FC and 
breathlessness82-84.  
Inhaled iloprost was shown in a multicentre double blinded RCT to increase the 
number of patients meeting the primary endpoint, a composite of improvements 
in 6MWD and WHO-FC, compared with placebo85. It requires to be taken 6 to 9 
times a day and has similar side effects to the other prostanoids of nausea, 
flushing and headache.  
1.6.2.5 Emerging therapies 
Patients have for several years been treated with PDE5 inhibitors, ERAs and 
prostanoids, either singly or in combination, and these were the drugs available 
for use at the time of the studies described in the following chapters. More 
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recently new drugs have become available which offer new approaches to PAH 
therapy. Briefly, riociguat, a stimulator of soluble guanylate cyclase works to 
increase cGMP in the NO/cGMP pathway and thus promote vasodilation. The 
PATENT and CHEST studies in patients with Group 1 and Group 5 PH respectively 
studied ricociguat in double blinded, placebo controlled trials and demonstrated 
a significant improvement in 6WMD, NTproBNP and WHO-FC with a longer time 
to clinical worsening and reduction in breathlessness also statistically significant 
in the Group 1 patients enrolled in PATENT11, 86. Riociguat is the first drug to be 
approved specifically for the medical management of patients with CTEPH. 
Selexipag is an oral selective IP prostacyclin receptor agonist. In a randomised 
double blinded placebo controlled trial it significantly reduced the risk of the 
primary endpoint, a composite of death or a PAH-related complication although 
there was no significant benefit on mortality alone12. 
1.6.2.6 Pulmonary endarterectomy 
If technically feasible, pulmonary endarterectomy (PEA) is the treatment of 
choice for patients with CTEPH as it is potentially curative therefore extensive 
assessment of the distribution and extent of organised thrombi, the functional 
and haemodynamic consequences of this and the general fitness and presence or 
absence of comorbid disease is undertaken prior to determining suitability for 
this surgery87. Consequently all patients with a diagnosis of CTEPH should be 
referred to an expert PEA centre for consideration of operability.  
The operation involves a median sternotomy before the patient is put on 
cardiopulmonary bypass. The pulmonary arteries on each side are dissected 
sequentially to remove the inner core of organised thromboembolic material, 
including the intima and superficial media88, 89.  
In hospital mortality at the time of PEA is less than 5%. Haemodynamic variables 
may return to normal or near normal with a consequent improvement in 
functional parameters. The long term prognosis is excellent with 1 year and 10 
year survival >90% and >70% respectively90, 91. 
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1.7 Exercise and pulmonary hypertension 
With exercise limitation a key symptom of PH, both at diagnosis and throughout 
the disease course, significant attention has focused on the role of exercise, 
both in helping to elucidate the pathophysiology and also as a mean of assessing 
disease severity and outcome. 
1.7.1 Exercise limitation 
It is reasonable to consider exercise the result of the process by which oxygen is 
transferred form the atmosphere, via the lungs and vasculature, to mitochondria 
in the peripheral muscle92. That oxygen consumption can be described by the 
Fick equation thus 
𝑉𝑂2 = 𝐶𝑂 ⋅ (𝐶𝑎𝑂2 − 𝐶𝑣𝑂2) 
where  VO2 = oxygen consumption     
  CO = cardiac output 
  CaO2 = arterial oxygen content 
  CvO2 = venous oxygen content. 
 
This equation can be expanded to highlight individual contributors to a given VO2 
as follows 
𝑉𝑂2 = 𝑆𝑉 ⋅ 𝐻𝑅 ⋅ 𝐻𝑏 ⋅ (𝑆𝑎𝑂2 − 𝑆𝑣𝑂2) 
where  SV = stroke volume      
  HR = heart rate       
  Hb = haemoglobin concentration    
  SaO2 = arterial oxygen saturation     
  SvO2 = venous oxygen saturation. 
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Therefore impairment of any one of stroke volume, heart rate, haemoglobin 
concentration, arterial oxygenation or oxygen extraction (and thus venous 
oxygen saturation) can cause a reduction in VO2 and thus exercise capacity. 
In PH the increased PA pressure and resultant RV failure lead to a reduction in 
the maximum achievable stroke volume93, 94, thus limiting the maximum VO2 
which can be reached. In addition, patients with PH exhibit a steeply climbing 
HR response to exercise and often fail to reach the predicted peak HR95 and iron 
deficiency anaemia is common96, 97. Furthermore a sharp decline in mixed venous 
oxygen saturation on exercise and ventilation-perfusion mismatch contribute to 
arterial desaturation on exercise98, 99. Thus, through several pathophysiological 
routes PH limits VO2 and therefore exercise capacity.  
The ventilatory response to exercise is also abnormal with markedly inefficient 
ventilation, most easily seen in the relationship between ventilation (VE) and 
carbon dioxide production (VCO2)100, 101. The VE for a given VCO2 on exercise is 
inversely related to the degree of physiological dead space and the “set point” 
at which CO2 is regulated102 as can be seen in the following equation 
(
𝑉𝐸
𝑉𝐶𝑂2
) =
𝑘
𝑃𝑎𝐶𝑂2 ⋅ (1 −
𝑉𝐷
𝑉𝑇
)
 
where  VE = ventilation 
  VCO2 = carbon dioxide production 
  PaCO2 = partial pressure of carbon dioxide 
  VD = dead space volume 
  VT = tidal volume. 
The increased ratio of VE to VCO2 seen on exercise in PAH is even greater in 
patients with CTEPH103, presumably due to the increased pulmonary vascular 
obstruction seen in that form of PH leading to an increased dead space fraction. 
It has been speculated that abnormalities of lung function may also contribute to 
an abnormal ventilatory response to exercise in patients with PAH. There is some 
evidence of peripheral airway obstruction in IPAH and a reduced inspiratory 
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capacity, which falls further with exercise, as a result of dynamic hyperinflation, 
has also been reported104, 105 however despite these findings and the more 
marked abnormalities seen in ventilatory efficiency, true ventilatory limitation is 
rare in PAH patients without comorbid lung disease106. 
It has been established that the peripheral muscle of patients with PH differs 
from that of healthy controls with reduced capillarity and alterations in 
mitochondrial function and muscle fibre type107-109. It has been suggested that 
these alterations in peripheral muscle function may limit exercise capacity by 
reducing oxygen extraction and thus limiting peak VO2 but evidence for this is 
limited in PAH110. 
1.7.2 The abnormal haemodynamic response to exercise 
In PAH there are marked abnormalities of the haemodynamic response which can 
be detected at RHC. Pressure measurements on exercise are complicated by a 
large respiratory swing, particularly in measurement of PAWP but also seen in 
measurement of PA pressures92, 111, 112. Pressure tracings from a patient with 
IPAH undergoing resting and exercise RHC are shown in Figure 1.1, 
demonstrating both the sharp rise in PA pressures and the marked respiratory 
swing.  
In health, mPAP and PAWP increase on exercise, with mPAP rising approximately 
0.5 – 3 mmHg per litre per minute increase in CO113 with a smaller rise seen in 
PAWP114. In PAH however there is a considerably steeper rise in mPAP with a 
smaller increment in CO than is seen in health, giving rise to a much steeper 
mPAP/CO relationship on exercise in PAH92, 115.  
The cardiac output response to exercise is blunted in PAH as a consequence of a 
failure to augment SV on exercise. In one study using cardiac MRI measurement 
of SV on submaximal exercise, healthy controls increased SV by approximately 
25% while no change was seen in SV in patients with IPAH93. In contrast to the 
control subjects in whom left ventricular (LV) and RV end diastolic volume (EDV) 
were both stable, in the patients with IPAH there was an increase in RVEDV and 
decrease in LVEDV. The total cardiac EDV was constant suggesting that on 
exercise there was progressive failure of the RV leading to the increase in 
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RVEDV, with consequent bowing of the interventricular septum into the LV, thus 
reducing the LVEDV. A reduction in RV ejection fraction (RVEF) was also seen 
suggesting that impaired forward flow from the RV on exercise was reducing LV 
filling. Together these mechanisms contributed to a failure to augment SV on 
exercise in the IPAH patients. Similar results were seen in an earlier study which 
also found evidence of increased RV filling and reduced LV filling, and saw a 
reduction in SV on exercise in patients with what was then known as primary 
pulmonary hypertension116.  
While RHC is required to confirm the diagnosis of PH, serial measurements over 
time are impractical due to the invasive nature of the test. It is though helpful 
in our understanding of exercise limitation in PH to understand the contribution 
of this abnormal haemodynamic response.  
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Figure 1.1 Right heart catheterisation pressure traces at rest and on exercise for a patient 
with idiopathic pulmonary arterial hypertension. PAP: pulmonary artery pressure; PAWP: 
pulmonary artery wedge pressure. 
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1.7.3 Noninvasive assessment of the exercise response 
1.7.3.1 Cardiopulmonary exercise test response profiles in pulmonary 
arterial hypertension 
Cardiopulmonary exercise testing (CPET) is the gold standard method of 
evaluating the cause of exercise limitation in patients with heart and lung 
disease117. It provides information not only on the degree of impairment but also 
on the relative contribution to that impairment of abnormalities of ventilation, 
gas exchange, and oxygen transport and delivery, enabling a more in depth 
diagnostic assessment. When performed in an experienced centre repeat testing 
demonstrates high reproducibility of measurements118. 
Pulmonary vascular disease is associated with a characteristic exercise response 
profile101, 119-124 and this is demonstrated in Figure 1.2 in a series of selected 
panels taken from the 9 panel plot output of a CPET carried out in a patient with 
IPAH at the time of diagnosis, prior to commencement on pulmonary vasodilator 
therapy. Patients demonstrate a shallower than normal VO2 / work rate (WR) 
slope and achieve significantly lower peak VO2 levels compared with healthy 
individuals.  A reduced peak oxygen pulse, i.e. VO2 / HR, is also seen. 
Considering again the Fick equation as shown in Chapter 1.7.1, 
𝑉𝑂2 = 𝐶𝑂 ⋅ (𝐶𝑎𝑂2 − 𝐶𝑣𝑂2) 
and that CO is the product of SV and HR, dividing both sides by HR gives 
𝑉𝑂2
𝐻𝑅
= 𝑆𝑉 ⋅ (𝐶𝑎𝑂2 − 𝐶𝑣𝑂2) 
and thus oxygen pulse is closely related to stroke volume. The low oxygen pulse 
seen on CPET in patients with PAH therefore represents the failure to augment 
SV described in Chapter 1.7.2. Patients also show an accelerated HR response, 
seen as a steep VO2 / HR slope. A high VE / VCO2 slope and high VE /VCO2 at 
anaerobic threshold are characteristic of the ventilatory inefficiency seen in PAH 
and a low end tidal CO2 (PETCO2) is also seen, indicative of the abnormal gas 
exchange occurring in PAH. 
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Figure 1.2 Typical CPET responses of a patient with PAH. The solid lines in A), B) and C) 
indicate the predicted peak values of the respective variables. The dashed line in A) 
represents a VO2/WR slope of 10 ml/min/Watt – a healthy response would parallel this line. 
Note the more shallow VO2/WR slope and reduced peak VO2 in PAH. Reduced peak oxygen 
pulse is seen in B). Steep heart rate response and VE/VCO2 slope are evident in C) and D) 
respectively with the predicted response corridors indicated by dashed lines. E) displays a 
markedly elevated ventilatory equivalent of CO2 while F) shows reduced end-tidal CO2, 
demonstrating key elements of the abnormal gas exchange response in PAH. 
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1.7.3.2 Cardiopulmonary exercise testing and prognosis 
CPET variables have in a number of studies been shown to predict outcome in 
patients with PAH. One study of incremental CPET in patients with PAH using 
either treadmill or cycle ergometer found that peak VO2, PETCO2, VE/VCO2 slope, 
peak systolic and diastolic blood pressure (BP) and peak HR were all predictive 
of survival on univariate analysis with peak VO2 and peak systolic BP remaining 
significant on multivariate analysis125. A similar study found peak VO2 and change 
in HR on exercise to be predictive of survival on multivariate analysis with those 
patients with lower peak VO2 and a smaller increase in HR on exercise having a 
poorer survival126. Peak HR was also found to be associated with survival in a 
further study of patients with IPAH, which also reported that the VE/VCO2 slope 
was predictive of survival127 
Patients with Group 1 PAH undergoing serial CPETs were assessed for survival in 
a prospective longitudinal study. The study authors found that the presence of a 
right to left shunt was predictive of mortality while in those patients without a 
right to left shunt, a higher VE/VCO2 ratio at anaerobic threshold (AT) was 
predictive of increased mortality128. A study of patients with IPAH and those with 
PAH associated with other conditions such as connective tissue disease, 
anorexigen use, liver cirrhosis and congenital left to right shunting found that 
although no clear predictor of survival was seen in the associated PAH group, 
peak VO2 was predictive of time to clinical worsening and VE/VCO2 at AT was 
predictive of survival on multivariate analysis129. A retrospective analysis of 
patients diagnosed with PAH or CTEPH who had undergone CPET at baseline 
found that patients with a lower VE/VCO2 slope, higher peak VO2 and greater 
increase in oxygen pulse from rest to peak exercise had significantly better 
survival on univariate analysis130. On multivariate analysis only the increase in 
oxygen pulse remained significant. 
1.7.3.3 Cardiopulmonary exercise testing and treatment response 
Studies of the use of CPET to detect a response to treatment have yielded mixed 
results. Small uncontrolled studies have shown an improvement in peak VO2 on 
long term therapy with intravenous prostacyclin131 and an increase in peak VO2 
and reduction in VE/VCO2 slope with nebulised iloprost132. A study of 28 patients 
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with PAH in which 14 continued on existing treatment and 14 were given 
additional treatment with sildenafil, found that there were improvements in 
VE/VCO2 at AT, PETCO2 at AT and peak oxygen pulse in the group treated with 
sildenafil. 
However in a considerably larger placebo controlled RCT of treatment with 
sitaxsentan, STRIDE-1, the ability of CPET to detect a treatment response was 
limited with only an increase in percent predicted peak VO2 in the higher 
treatment dose group reaching statistical significance133. No improvements were 
seen in either of the two treatment dose groups compared with placebo for 
other CPET variables studied, namely VO2 at AT and VE/VCO2 at AT. It has been 
suggested that these negative findings may be explained by the relatively 
complex nature of cardiopulmonary exercise testing and the multicentre nature 
of the study, perhaps leading to less accurate results when CPET was performed 
in centres with less experience134. 
1.7.3.4 The 6 minute walk test in pulmonary hypertension 
The most common exercise test used in the assessment and monitoring of 
patients with PH is the 6minute walk test (6MWT)92. In contrast to incremental 
CPET the 6MWT is a submaximal test which relies mainly on aerobic rather than 
anaerobic metabolism135. Its popularity stems partly from the lack of specialist 
equipment required, with the only significant requirement a straight and quiet 
30 metre corridor136, and partly from the significant correlations seen between 6 
minute walk distance (6MWD) and other measures of exercise performance, 
function and haemodynamic measurements. 
In patients with IPAH the 6MWD has been shown to correlate significantly with 
peak VO2, oxygen pulse and VE/VCO2 slope as measured on maximal CPET137. In 
the same study a modest but statistically significant correlation was also seen 
with baseline CO and total pulmonary resistance (TPR) but not with mPAP. The 
6MWD was also seen to decrease in proportion with the severity of the functional 
class. In a separate study measuring gas exchange variables during 6MWT a 
correlation was seen between the 6MWD and the measured VO2 achieved during 
the walk test135. Baseline 6MWD has been demonstrated to correlate with 
measures of quality of life and in addition the change in 6MWD on treatment has 
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been also been shown to correlate with change in quality of life138. The change 
in 6MWD has been shown separately to correlate significantly with cardiac index 
and PVR139. 
When measured at baseline, 6MWD has consistently been found to be predictive 
of survival in trials of pulmonary vasodilator treatment in PAH140. The strong 
predictive relationship with survival has also been seen in analyses of registry 
data and therefore baseline 6MWD has been included in risk scores from the 
French registry6 and the North American REVEAL registry141, and also in the 
Scottish Composite Score derived from UK data142. Although the prognostic 
strength is high in IPAH it is less strong and may be lost in patients with Group 1 
PAH associated with other conditions such as connective tissue disease129, 143.  
Interestingly, although 6MWD improves with pulmonary vasodilator treatment, 
hence its inclusion in multiple clinical trials140, and the change in 6MWD 
correlates with the change in haemodynamics as described above, the size of the 
change does not appear to have prognostic significance. Several studies have 
failed to demonstrate a prognostic effect of the change in 6MWD140, 144-146. It 
appears that the change in 6MWD accounts for only a minor part of the overall 
treatment effect147. The correlation between the change in 6MWD and the 
change in haemodynamics is stronger than that with change in RV function148 but 
it is the change in RV function which is most strongly linked to outcome149. 
A further drawback of using 6MWD as an outcome measure is the ceiling effect, 
whereby it is more difficult to see an improvement in subjects with a higher 
baseline 6MWD than in those with a lower baseline 6MWD150-153. 
Despite these drawbacks however the 6MWT remains an integral part of the 
assessment and monitoring of patients with PAH, both in routine practice and in 
clinical trials. 
  
45 
 
1.8 Noninvasive assessment of the pulmonary circulation 
The haemodynamic status of the RV and pulmonary circulation is key to the 
diagnosis and assessment of patients with PH. However while RHC is the gold 
standard method of this repeat procedures are unattractive due to the invasive 
nature of the test. Research is therefore ongoing into potential noninvasive 
modes of assessing the haemodynamic abnormalities. In addition to 
echocardiography as described in Chapter 1.4.3, cardiac MRI is increasingly being 
used in the noninvasive assessment of the pulmonary circulation of patients with 
PH. Inert gas rebreathing (IGR) has also provoked interest as a potentially useful 
measure of haemodynamic change which again can be measured noninvasively. 
1.8.1 Cardiac magnetic resonance imaging 
MRI is an attractive method of assessing the right heart as it is noninvasive, uses 
no ionising radiation and provides information on both the structure and the 
function of the heart. Despite being considerably more expensive than 
echocardiography and less widely available, cardiac MRI has evolved over recent 
years to become the gold standard method of assessing the structure and 
function of the heart in a range of diseases including pulmonary hypertension154-
159. While some patients find MRI difficult to tolerate due to long scan times, 
claustrophobia and the need to perform repeated breath hold manoeuvres, 
newer technology has enabled scans to be performed more quickly and with real 
time acquisition160, 161 thus improving patient tolerance.  
In PH cardiac MRI can allow assessment of RV structure, size and function, and 
provide information on flow form the RV into the pulmonary circulation with 
measurements including SV, CO and PA distensibility162. Studies in patients with 
PAH have described impairment of RV systolic function, quantifiable by 
measurement of RVEF, SV and CO, with increased RVEDV and RV end systolic 
volume (RVESV) compared with control subjects155, 163, 164. MRI however is not 
able to measure actual PA pressures and therefore cannot replace RHC as a 
diagnostic tool. Correlations between PA pressure and cardiac MRI derived 
variables including the average velocity of pulmonary blood flow (PBF), septal 
curvature, relative area change of the main PA and the ventricular mass index 
(the ratio of RV mass to LV mass) have been seen raising the possibility that with 
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refinement cardiac MRI may have a role to play in the noninvasive diagnostic 
assessment of patients with PAH165-168. 
1.8.2 Inert gas rebreathing 
Inert gas rebreathing (IGR) is a long established technique for the noninvasive 
measurement of CO. It is based on the principle that when rebreathing in a 
closed circuit, the rate at which a specified gas dissolves in blood is proportional 
to the blood flow through the pulmonary capillaries. The PBF is equal to the 
cardiac output in the absence of a significant intracardiac or intrapulmonary 
shunt. Initially studied using acetylene rebreathing169 it was shown to have good 
agreement with more traditional techniques of measuring CO, namely the Fick 
and thermodilution methods, including in patients with Group 1 PH170.  
A modern refinement of this technique using a gas mixture of sulphur 
hexafluoride and nitrous oxide coupled to a rapid photoacoustic gas analyser has 
been shown to have good limits of agreement for SV measured by this method 
when compared with SV measured by cardiac MRI and by thermodilution in 
patients with PAH171. This method compares favourably with the conventional 
mass spectrometers previously used with IGR as it is more user friendly, lighter 
and less expensive172. Furthermore it can be used in the presence of fibrotic lung 
disease while maintaining good agreement with CO measured invasively by the 
indirect Fick method173. 
This method of IGR has been studied successfully in patients with chronic heart 
failure. In one study measurement of CO was seen to agree closely with 
measurements made by the thermodilution and direct Fick methods174. A 
separate study in patients with heart failure showed that this method of IGR 
could be used to measure CO successfully at rest and on exercise175, while a 
further study demonstrated that such measurements of CO made at peak 
exercise can predict survival in patients with chronic heart failure176. In a study 
of 24 patients with Group 1 or Group 4 PH either starting treatment de novo or 
undergoing modification of existing treatment, PBF and SV were seen to increase 
significantly at 3 months150. The further role of IGR in the assessment and 
monitoring of patients with PAH remains to be explored. 
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1.9 Hypotheses and aims 
This thesis aims to investigate the extent to which novel exercise derived 
variables and noninvasive haemodynamic measurements can enhance the 
assessment and monitoring of patients with pulmonary hypertension. The 
following hypotheses were examined in clinical studies: 
1. that there is impairment of peripheral muscle oxygen extraction on 
exercise in patients with Group 1 and Group 4 pulmonary hypertension, 
2. that the oxygen uptake efficiency slope is strongly correlated with peak 
VO2 in PH, that it is valid as a submaximal measure of exercise 
performance in groups I and IV PH and that it predicts survival in patients 
within these disease groups, 
3. that prolonged rates of recovery of heart rate and VO2 after incremental 
CPET in patients with precapillary PH will be associated with poorer 
survival and 
4. that inert gas rebreathing may detect early changes in stroke volume 
after institution or alteration of pulmonary vasodilator therapy and that 
this change will be associated with later functional improvement.  
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2 Materials and methods 
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2.1 The Scottish Pulmonary Vascular Unit 
All patients recruited for the studies documented in this thesis were attending 
the Scottish Pulmonary Vascular Unit (SPVU) for diagnosis and treatment of PH. 
The SPVU was founded in 1990 and although based in Glasgow it is a tertiary 
referral centre for PH and is the sole centre in Scotland for managing adult 
patients with PH. Scotland has a population of 5.3 million of whom 
approximately 4.4 million are aged 16 years or over and therefore potentially 
served by the SPVU. The National Audit of Pulmonary Hypertension gathers data 
from all eight specialised pulmonary hypertension centres in the United 
Kingdom, seven of which treat adult patients and there is one paediatric centre. 
The most recent data from this audit, covering April 2014 to March 2015, 
demonstrates a referral rate to SPVU of 42 per million population, with a point 
prevalence of 82 cases of pulmonary hypertension per million population14.  
During the years 2012-2014 a total of 608 patients had referrals accepted to 
SPVU and 233 patients were diagnosed with group 1, 4 or 5 PH. At 31/12/14 
there were 341 patients diagnosed with group 1, 4 or 5 PH with active ongoing 
follow up within SPVU. Due to the structure of the service in Scotland, with only 
the SPVU permitted to prescribe pulmonary vasodilator therapies, it is 
reasonable to assume that all patients in Scotland with a known diagnosis of 
precapillary PH are treated under the auspices of the SPVU.  
 
2.2 World Health Organisation functional class 
The World Health Organisation functional class (WHO-FC) for pulmonary 
hypertension was modified from the New York Heart Association classification 
for describing the functional impact of heart failure. The WHO-FC has been used 
since 1998 and is now well established in the assessment of patients with PH4 
(Table 2.1). The timing of WHO-FC assessment is documented in the chapters 
detailing the specific methods for each study. 
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WHO functional class 
 
Class I Patients with pulmonary hypertension but without resulting 
limitation of physical activity. Ordinary physical activity does 
not cause undue dyspnoea or fatigue, chest pain, or near 
syncope 
Class II Patients with pulmonary hypertension resulting in slight 
limitation of physical activity. They are comfortable at rest. 
Ordinary physical activity causes undue dyspnoea or fatigue, 
chest pain, or near syncope. 
Class III Patients with pulmonary hypertension resulting in marked 
limitation of physical activity. They are comfortable at rest. 
Less than ordinary activity causes undue dyspnoea or fatigue, 
chest pain, or near syncope. 
Class IV Patients with pulmonary hypertension with inability to carry 
out any physical activity without symptoms. These patients 
manifest signs of right heart failure. Dyspnoea and/or fatigue 
may even be present at rest. Discomfort is increased by any 
physical activity. 
Table 2.1 WHO functional classification of pulmonary hypertension 
 
 
2.3 Cambridge Pulmonary Hypertension Outcome 
Review score 
The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) score is a 
pulmonary hypertension specific patient-completed questionnaire and was used 
to assess health related and general quality of life177 (Appendix 1). It asks 
questions across three domains: symptoms, activities and quality of life, with 
higher scores reflecting poorer quality of life. 
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2.4 N-terminal pro-brain natriuretic peptide 
N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured on venous 
blood sampled by standard venepuncture and collected in vacuum tubes 
containing ethylenediaminetetraacetic acid (EDTA). In patients undergoing an 
exercise protocol as part of the studies blood for NT-proBNP analysis was 
sampled prior to the exercise component of the assessment. 
 
2.5 Six minute walk test 
Six minute walk tests (6MWT) were carried out by the respiratory physiologists at 
the Golden Jubilee National Hospital, by Ms Val Pollock, clinical trial nurse, or 
by Dr SD Thomson. All were conducted in accordance with American Thoracic 
Society guidelines136. 
 
2.6 Incremental cardiopulmonary exercise test 
Maximal incremental cardiopulmonary exercise tests (CPETs) were conducted in 
accordance with established guidelines178 using an electromagnetically braked 
cycle ergometer (ergoselect 200, ergoline GmbH, Bitz, Germany). CPETs were 
carried out by a trained respiratory physiologist with medical supervision (Dr SD 
Thomson). Patients wore a tight fitting face mask connected to a metabolic cart 
for breath by breath measurement of gas exchange variables (Medisoft, Sorinnes, 
Belgium; lovemedical, Manchester, United Kingdom). Oxygen saturations were 
measured transcutaneously by finger or ear probe and a continuous 12 lead 
electrocardiograph (ECG) was performed for cardiac monitoring. Systemic blood 
pressure was measured noninvasively by either an automated electronic or a 
manual sphygmomanometer.  
Predicted values were calculated using published equations179 and maximum 
voluntary ventilation (MVV) was estimated as 35 x forced expiratory volume in 1 
second (FEV1)180. CPET was contraindicated if the patients had a history of 
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exertional presyncope, syncope or arrhythmia, or the presence of a neurological 
or musculoskeletal deficit which would limit exercise performance.  
Patients sat at rest on the bicycle for an initial period of a few minutes after 
fitting of the mask and connecting the monitoring equipment. Recording was 
commenced and a formal rest period of two minutes undertaken. The subjects 
then began a 3 minute unloaded cycling phase at a cadence of 60 revolutions per 
minute which was maintained throughout the test. After 3 minutes the load was 
gradually applied to the ergometer. The rate of increase of work rate through 
the loaded cycling phase was estimated by the respiratory physiology team prior 
to the test on the basis of each patient’s description of their functional 
capabilities with the aim that the patient would be able to achieve 8 to 12 
minutes of loaded cycling before reaching their symptomatic limit. Recordings 
were made of cardiac, gas exchange and ventilation variables continuously 
throughout the test. Recording continued in the recovery phase, usually for at 
least 2 minutes. Patients were encouraged to continue to cycle at a reduced 
cadence and with no load applied during this recover period. 
 
2.7 Right heart catheterisation and exercise right heart 
catheterisation 
2.7.1 Resting right heart catheterisation 
Right heart catheterisation (RHC) is the gold standard method for diagnosing 
pulmonary hypertension and forms a routine part of each patient’s initial 
diagnostic assessment. All the resting RHCs included in these studies were 
performed as part of routine clinical care at the time of first diagnosis of PH. 
None of the patients were on pulmonary vasodilator therapy at the time of the 
RHC. All RHCs were performed with the patient awake. On occasion some mild 
intravenous sedation with midazolam was used to improve tolerance but patients 
remained alert throughout the procedure. All RHCs were conducted supine.  
To facilitate access to the central venous system an 8Fr venous introducer 
sheath was sited in the right internal jugular vein under direct ultrasound 
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visualisation with x-ray screening used to confirm the position. This was most 
often carried out the afternoon prior to the catheterisation session and the 
sheath was secured in place with a silk suture and an occlusive dressing. If it was 
not possible to site the sheath in the right internal jugular vein then it was 
placed instead in either the right femoral vein or left internal jugular vein, again 
using direct ultrasound visualisation and x-ray screening to confirm position.  
A balloon-tipped flow-directed pulmonary arterial (Swan-Ganz) catheter was 
inserted through the introducer sheath and into the venous system. Under 
fluoroscopy screening the catheter was passed into the right atrium, right 
ventricle and pulmonary artery181. Measurements of right atrial pressure (RAP), 
right ventricular systolic pressure (RVSP), pulmonary arterial systolic, diastolic 
and mean pressures (PASP, PADP and mPAP respectively), and pulmonary artery 
wedge pressure (PAWP) were made using a pressure transducer zeroed 
externally at the level of the left atrium. This level was estimated as the point 
in the midaxillary line at the midthoracic level. PAWP was obtained by inflation 
of the balloon with the catheter in a pulmonary artery branch and confirmed by 
assessment of the resulting pressure wave trace. Measurements were captured 
and recorded using commercially available equipment and software (GE 
Healthcare, Buckinghamshire, United Kingdom). Pulmonary vascular resistance 
(PVR) was measured in Wood units and calculated as transpulmonary gradient 
(TPG) divided by cardiac output (CO) in litres/minute where TPG is the 
difference between mean pulmonary artery pressure and pulmonary artery 
wedge pressure in mm Hg, i.e.  
𝑃𝑉𝑅 =
(𝑚𝑃𝐴𝑃 − 𝑃𝐴𝑊𝑃)
𝐶𝑂
 
Cardiac output was quantified by the thermodilution method182. Although the 
direct Fick method of cardiac output measurement is the gold standard the 
thermodilution method has long been accepted as a more practical alternative, 
is standard practice within the SPVU and has shown good agreement with the 
direct Fick method in patients with pulmonary hypertension, even in the context 
of low cardiac output or severe tricuspid regurgitation170. Cardiac output 
measurements were repeated until three readings were obtained with variability 
of ≤10% and the mean of these three readings was recorded as the CO. 
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Mixed venous oxygen saturations (SvO2) were measured by withdrawing 3ml of 
blood from the distal pulmonary arterial port of the catheter into a heparinised 
blood gas syringe (BD, Oxford, United Kingdom). This sample was immediately 
processed in a blood gas analyser (RAPIDLab 1265, Siemens Healthcare, 
Germany). 
In patients not undergoing subsequent exercise RHC (described in 2.7.2) the 
catheter was removed under fluoroscopy screening. The introducer sheath was 
removed and the wound closed with direct pressure and the application of an 
airtight dressing. 
 
2.7.2 Exercise right heart catheterisation 
Exercise right heart catheterisation was performed immediately following the 
completion of the resting RHC (described in Chapter 2.7.1). The introducer 
sheath and pulmonary arterial catheter were left in situ. Patients in whom the 
introducer sheath had had to be inserted into the femoral vein did not 
participate in the exercise RHC due to the difficulty of pedalling with a venous 
access point in the groin. An electromagnetically braked cycle ergometer 
(Corival Supine, Lode, Groningen, Netherlands) was placed on the cardiac 
catheterisation table and its position adjusted to allow comfortable supine 
cycling for each patient. The ergometer was secured to the table by bolts 
attaching it to the table’s side rails to maintain its position during cycling. The 
patient’s feet were then strapped to the pedals. This led to a slight elevation of 
the legs compared with the fully supine resting RHC. After five minutes of rest in 
this position repeat measurements were taken of RAP, RVSP, PASP, PADP, mPAP, 
PAWP and CO (described in 2.7.1) and these were taken as the resting 
measurements for comparison with the subsequent exercise results.  
In contrast to the upright CPET which used an incremental work rate protocol, 
the supine exercise test used a constant work rate protocol. Such protocols are 
ideally suited to measurements of gas exchange178 and arterial blood gas 
measurements made after five minutes of constant work rate cycling at 70% of 
the peak work rate achieved on a maximal incremental CPET approximate those 
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measured at the peak of the incremental test183. Furthermore it has been shown 
in several studies that exercise capacity is significantly reduced in the supine 
compared to upright position during moderate to high intensity cycling and that 
this is most marked during constant work rate exercise184-186. Therefore the 
supine constant work rate was calculated as 50% of the total work rate achieved 
in the maximal upright cardiopulmonary exercise test which each patient had 
performed two days earlier.  
The patients were asked to start cycling, initially with zero resistance, at a 
cadence of 60 revolutions per minute. The resistance was increased over 
approximately 30 seconds until the target work rate was reached. After 3 
minutes cycling at this work rate repeat measurements of PASP, mPAP, PADP 
and PAWP were made. Cardiac output was then measured but in contrast to the 
resting CO measurements, this was carried out in duplicate rather than triplicate 
given the time needed between each CO thermodilution procedure for the blood 
temperature to stabilise and the measurement system to reset. Pressure 
measurements were then repeated before finally a further pulmonary arterial 
blood sample was withdrawn for end exercise blood gas analysis (described in 
2.7.1).  
Following the withdrawal of this blood sample patients were instructed to slow 
and then stop pedalling. Feet were unstrapped from the pedals and legs lowered 
onto the catheterisation table. The ergometer was removed from the table and 
the catheter was withdrawn from the pulmonary arterial system under 
fluoroscopy screening. The introducer sheath was removed (described in 2.7.1). 
 
2.8 Oxygen uptake efficiency slope 
2.8.1 Calculation of oxygen uptake efficiency slope 
Oxygen uptake efficiency slope (OUES) is an index derived from breath by breath 
values of ventilation (VE) and oxygen uptake (VO2) measured over the course of 
an incremental cardiopulmonary exercise test187. CPETs were carried out as 
described in Chapter 2.6. For each subject the breath by breath measurements 
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of VE and VO2 from onset of loaded cycling until peak exercise were extracted 
from the CPET reporting software and entered into a spreadsheet (Excel, 
Microsoft, Redmond, Washington, USA). 
The relationship between VE and VO2 during an incremental CPET is not linear 
(Figure 2.1). 
 
Figure 2.1 Relationship between minute ventilation and oxygen consumption during a 
maximal incremental cardiopulmonary exercise test. VO2: oxygen consumption, VE: minute 
ventilation  
 
Logarithmic transformation of the minute ventilation data was therefore 
performed and the resulting values plotted against VO2, producing a linear 
relationship with VO2 where: 
𝑉𝑂2 = 𝑎 𝑙𝑜𝑔𝑉𝐸 + 𝑏 
and a is defined as the OUES (Figure 2.2). 
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Figure 2.2 Oxygen uptake efficiency slope calculation. VO2: oxygen consumption; logVE: log 
transformed minute ventilation; OUES is the gradient of the line formed 
 
2.8.2 Conversion of CPET plots into numerical data for OUES 
calculation 
The value of OUES as a predictor of survival in PH was assessed (Chapter 4.3.3). 
Some of the earlier cardiopulmonary exercise tests had no data table available 
and therefore no breath by breath minute ventilation and oxygen uptake values 
were available for calculation of OUES. The original plots of VE and VO2 versus 
time were therefore converted back into numerical data using digitising 
software (GetData Graph Digitizer v2.26, http://getdata-graph-digitizer.com/).  
The original paper plots were scanned then imported into PowerPoint 
(PowerPoint, Microsoft, Redmond, Washington, USA). An adjustable grid with 24 
vertical lines was created in Word (Word, Microsoft, Redmond, Washington, USA) 
then also imported into PowerPoint and overlaid on the plot to be digitised with 
the first and last lines positioned over the five and fifteen minute time points on 
the x axis (Figure 2.3). The five minute time point was chosen as it represents 
the onset of loaded cycling. The resulting image was saved as a TIF file. 
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Figure 2.3 Plot of minute ventilation versus time with digitising grid overlaid and positioned 
between the 5 and 15 minute time points on the x axis. VE: minute ventilation in 
litres/minute, Time: exercise time in minutes 
 
The TIF file was then opened in the digitising programme. Scales on the x and y 
axes were set by allocating minimum and maximum values along each axis. Using 
the manual digitising function the central point between each pair of gridlines 
was selected and its values on the x and y axes recorded in a table. The plot for 
the same patient as Figure 2.3 with digitising points selected is shown in Figure 
2.4.  
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Figure 2.4 Plot of minute ventilation versus time with digitising grid overlaid and points 
manually selected shown in pink. VE: minute ventilation in litres/minute, Time: exercise time 
in minutes 
 
The output table with values of the x (time) and y (minute ventilation) axes for 
each digitising point was then exported to Excel and OUES calculated as 
described in Chapter 2.8.1. 
Due to the nature of the technique it is possible for there to be small errors in 
the values obtained by digitising individual data points. However any such errors 
would be random rather than systematic. Furthermore their effect would be 
minimised by the subsequent calculation of the OUES as a slope constructed of 
multiple data points. It was therefore felt that this technique was a valid 
method for the extraction of exercise test data and OUES calculation. 
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2.9 Measurement of heart rate and oxygen consumption 
recovery following incremental cardiopulmonary 
exercise test 
Cardiopulmonary exercise tests for the patient group used for analysis of oxygen 
uptake efficiency slope and survival (Chapter 4.3.3) were reviewed and those 
with at least 60 seconds of technically acceptable recovery data recorded were 
selected. Only tests with available data tables were included. The values of both 
heart rate (HR) and oxygen consumption (VO2) at peak exercise and at 30 
seconds, 60 seconds and 120 seconds into recovery were recorded. The recovery 
was calculated as an absolute reduction from peak values and by taking the 
value at each time point as a percentage of the peak exercise value. Survival 
analysis was then undertaken as described in Chapter 2.10. 
 
2.10 Survival analysis 
2.10.1 Cox proportional hazards model 
To identify predictors of all-cause mortality a Cox proportional hazards model 
was employed (IBM SPSS Statistics, International Business Machines Corp, Armok, 
New York, USA). Right censoring was used with survival time calculated from the 
date of diagnosis to the date of death or date of censor. Patients were censored 
at the time of death, transplantation, pulmonary endarterectomy, or loss to 
follow up (taken as the last date of clinical contact), or at the time of data cut-
off (25th September 2013). Univariate analysis was performed on a series of 
candidate variables to determine which were predictors of mortality. These 
variables were then assessed for collinearity using either Pearson or Spearman 
correlation, depending on the distribution of each variable, and by calculation of 
the variance inflation factor (VIF). Those with a high correlation (r or ρ > 0.7) or 
a VIF > 3 were not included in the multivariate analysis.  
Remaining variables with a p value less than a predefined limit in the univariate 
analysis were analysed in the multivariate model with backwards selection. One 
variable for every ten events (deaths) was included in the model to avoid 
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overfitting. A p value < 0.05 by likelihood ratio test was considered statistically 
significant.  
2.10.2 Kaplan-Meier analysis 
Kaplan-Meier analysis was used to compare survival rates for different groups 
with all-cause mortality the endpoint (IBM SPSS Statistics). Survival time was 
calculated and censoring performed as described in Chapter 2.10.1. Log rank 
tests were used to compare the groups and Kaplan-Meier survival curves 
produced. A p value < 0.05 was considered statistically significant. 
 
2.11 Inert gas rebreathing in the assessment of treatment 
response in pulmonary hypertension 
2.11.1 Operation of inert gas rebreathing with Innocor 
Inert gas rebreathing (IGR) was used to determine pulmonary blood flow and 
therefore right ventricular stroke volume through rebreathing an oxygen 
enriched mix of nitrous oxide (N2O) and sulphur hexafluoride (SF6) (Innocor, 
Innovision A/S, Odense, Denmark). This is an established technique which has 
been validated for use in heart failure172, 174, 175 and pulmonary hypertension171, 
172. To perform the rebreathing manoeuvre patients wore a nose clip and 
breathed via a mouthpiece and filter connected to a valve either open to the 
ambient air or to a rebreathing Douglas bag containing a mix of oxygen, N2O, 
SF6, and room air (Figure 2.4).  
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Figure 2.5 Innocor set-up for inert gas rebreathing manoeuvre.  
 
Breath by breath respired gases were measured continuously at the mouthpiece 
via a sampling line connected to a rapid infrared photoacoustic gas analyser. 
Before each IGR test a 3 litre Douglas bag was filled with a mix of ambient air 
via an air pump and a bolus of gas from the Innocor gas cylinder. The cylinder 
contained 94% oxygen, 5% N2O and 1% SF6 and a bolus fraction of 10% was used 
routinely to give a final concentration in the Douglas bag of 28.3% oxygen, 0.5% 
N2O and 0.1% SF6. The volume of the gas mixture in the bag before each IGR 
measurement was 200ml less than the highest volume of: 44% of the predicted 
vital capacity188, the tidal volume during the preceding 5 breaths or the volume 
required to ensure the gas concentrations remained below the maximum CO2 
limit and above the minimum O2 limit. These limits were set by default to a CO2 
less than 8% and an O2 greater than 13%. A higher bolus fraction of 20% was used 
for IGR measurement on exercise to compensate for the increased ventilatory 
demand.  
Patients breathed via the mouthpiece with the valve open to the air supply until 
the appropriate time for each IGR measurement. At that point the operator (Dr 
SD Thomson) then started each measurement by priming the valve to open at 
the end of the next expiration. From the point at which the valve opened the 
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patients then breathed in a closed circuit with the rebreathing bag. The patient 
was instructed to breathe deeply enough to empty the bag with each inspiration 
then to exhale normally with a target respiratory rate of 20-30 breaths per 
minute. Usually fewer than 8 breaths were required to complete the rebreathing 
measurement. Given that N2O is highly soluble in blood it left the rebreathed gas 
mixture at a rate proportionate to the pulmonary blood flow (PBF). SF6 is 
insoluble in blood and therefore remained in the closed circuit between alveoli 
and rebreathing bag and was used to determine the total volume from which the 
N2O disappeared, known as the total systemic volume. Calculation of the total 
systemic volume and PBF was performed by the Innocor IGR machine by 
established methods189 which are described in Sections 2.11.1 and 2.11.3 
respectively. 
2.11.2 Calculation of total systemic volume  
The total systemic volume is the sum of the volumes of the lungs, the 
rebreathing bag and the deadspace of the mouthpiece and rebreathing valve. 
During each rebreathing manoeuvre the concentration of SF6 declined from the 
initial concentration in the rebreathing bag until fully mixed with the air in the 
lungs and an equilibrium reached. The difference between maximum and 
minimum SF6 concentrations within each breath was analysed continuously and a 
mixing level calculated as the difference between these maximum and minimum 
concentrations divided by their mean. When this level fell below a threshold 
value of 15% the gases were considered adequately mixed and estimation of 
pulmonary blood flow could begin (Chapter 2.11.3). This usually occurred within 
3-5 breaths. A maximum limit of 30 seconds was allowed for each IGR 
measurement to ensure there was no recirculation of dissolved N2O back into the 
pulmonary circulation as this would have created an error within the 
measurements. 
Given the volumes of the rebreathing bag and deadspace were known the total 
systemic volume could be determined from the dilution of insoluble SF6, i.e. 
from the ratio of the initial concentration of SF6 in the rebreathing bag, taken as 
the peak concentration measured during the first inspiration, to the 
concentration of SF6 at equilibrium.  
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The total systemic volume was subject to change throughout the rebreathing 
measurement due to changes in CO2 excretion while O2 uptake remained 
constant. The IGR manoeuvre required patients to breathe a little more deeply 
and with slightly increased respiratory rate compared with normal ventilation. 
This increased ventilation caused a lower alveolar partial pressure of CO2 as PBF 
remained constant. The resulting increased diffusion gradient between the 
capillaries and the alveoli led to increased CO2 excretion into the lungs and 
therefore an increase in the total systemic volume. However as the CO2 level 
rose, the gradient lessened and the rate of CO2 excretion fell causing the volume 
to shrink. For the purpose of calculation of PBF the total systemic volume was 
taken at time “zero”, actually the midpoint of the first inspiration. At this point 
the SF6 would not yet have adequately mixed and therefore the SF6 
concentration at time zero was calculated by back extrapolation from the point 
at which adequate mixing was achieved (Figure 2.6).  
The total systemic volume at time zero was calculated as 
𝑉𝑡𝑜𝑡 =
[𝑆𝐹6]𝑖
[𝑆𝐹6]𝑒𝑞
⋅ 𝑉𝑅𝐵 
where 
 Vtot  = the total systemic volume at time zero   
 [SF6]i  = the initial concentration of SF6 in the rebreathing bag
 [SF6]eq  = the concentration of SF6 once equilibrium achieved,  
    back extrapolated to time zero    
 VRB  = the volume of the rebreathing bag 
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Figure 2.6 Concentration of insoluble SF6 during rebreathing. The black line through the 
expiratory points once adequate mixing was achieved (represented by vertical blue bars) 
allowed back extrapolation to determine the SF6 concentration at time zero (t=0). 
 
2.11.3 Calculation of pulmonary blood flow 
Pulmonary blood flow is that which perfuses the ventilated parts of the alveoli. 
It was calculated during inert gas rebreathing by measuring the rate at which 
blood soluble N2O disappeared from the rebreathed gas mixture. An initial, 
almost instant, fall in N2O was attributed to dissolution of the gas in the tissue of 
the lung while a subsequent more gradual decline occured due to dissolution in 
the perfusing pulmonary blood flow. This rate of decline was proportional not 
only to the PBF but also to the alveolar concentration of N2O and therefore the 
disappearance of N2O was described by a monoexponentially decreasing function 
of time. As described in chapter 2.11.2 the actual total systemic volume 
changed during each IGR manoeuvre. To account for this and for any incomplete 
mixing the N2O concentrations were “normalised” by adjusting for changes in the 
SF6 concentration. Representing the decay of the normalised N2O concentration 
in a semilogarithmic plot produced a linear relationship, the slope of which was 
proportionate to the PBF (Figure 2.7).  
66 
 
 
Figure 2.7 Semilogarithmic plot of normalised N2O on the y axis and time on the x axis. The 
regression line through the end-expiratory points once adequate gas mixing was achieved 
(vertical blue bars) was proportionate to the pulmonary blood flow. 
 
PBF was then calculated using the formula: 
𝑃𝐵𝐹 =  −𝛽 ⋅
𝑉𝑡𝑜𝑡 ⋅ 𝐶1 + 𝐶2
𝛼𝑏
 
where 
 β = slope of the regression line through the expiratory   
   points of the semilogarithmic normalised N2O    
   concentrations      
 Vtot = total systemic volume (STPD) (Chapter 2.11.2)   
 C1 = 760/(ambient pressure in mmHg – 47)    
 C2 = αt·Vt, constant to account for the dissolution of N2O in lung 
   tissue         
 αt = Bunsen solubility coefficient in tissue of N2O = 0.407 (STPD) 
 Vt = lung tissue volume (default 600ml)    
 αb = Bunsen solubility coefficient in blood of N2O = 0.412 (STPD) 
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In the absence of a significant intracardiac or intrapulmonary shunt pulmonary 
blood flow is equivalent to the right ventricular cardiac output and therefore the 
stroke volume was calculated by dividing PBF by heart rate. The Innocor 
software does have the ability to estimate and correct for shunting using the 
following formula: 
𝐶𝑂 =
1
(
1
𝑃𝐵𝐹) +
𝐶𝑎𝑂2 − 𝐶𝑐𝑂2
𝑉𝑂2
 
where 
 CO = cardiac output       
 PBF = pulmonary blood flow      
 CaO2 = arterial blood oxygen content (0.000139 × haemoglobin  
   concentration (g/dL) × arterial oxygen saturation (%) by  
   pulse oximetry)       
 CcO2 = pulmonary end-capillary blood oxygen content (0.000139 × 
   haemoglobin concentration (g/dL) × pulmonary end-capillary
   oxygen saturation (%))     
 VO2 = oxygen uptake (L/min) 
The algorithm assumes a pulmonary end-capillary saturation of 98%. The validity 
of this assumption in pulmonary hypertension has been questioned due to the 
increased ventilation/perfusion mismatch and lower mixed venous oxygen 
saturations seen in PH with previous work using the Innocor equipment in PH 
advocating against use of the shunt correction algorithm190. Therefore PBF was 
used for the IGR work included in this thesis without application of the shunt 
correction algorithm. 
2.11.4 Resting inert gas rebreathing protocol 
The first set of resting IGR measurements were made with the patient lying 
supine. At the first visit the subjects were shown how to perform an IGR 
manoeuvre and practice attempts with only air in the rebreathing circuit were 
performed until the patient could perform the test with ease. For most patients 
only 2 or 3 practice attempts were required. Patients at future visits who had 
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previously performed the IGR test were given a brief verbal reminder and a 
practice attempt was undertaken to ensure the IGR test could still be performed 
without difficulty. 
Patients lay at rest in the supine position for 10 minutes to ensure the recorded 
measurements would be a true reflection of the resting supine state. The first 
IGR manoeuvre was performed and the data recorded. In undertaking serial 
measurements it is necessary to ensure that the SF6 and N2O have washed out of 
the lungs and circulating blood. The N2O concentration had to be less than 
0.002% and the SF6 concentration less than 0.001% prior to each test and in 
practice at least 5 minutes was used between tests to ensure washout occurred. 
The IGR manoeuvres were repeated in the supine position until 3 technically 
acceptable results were obtained. 
Patients were then asked to sit on an upright cycle ergometer (ergoselect 200, 
ergoline GmbH, Bitz, Germany) and feet were strapped into the pedals. The 
Innocor was repositioned to enable comfortable upright measurements at rest 
and on exercise and ECG leads were connected for the later exercise component 
of the test. A further 10 minute rest period was required before measurement of 
PBF by IGR was performed. As with the supine measurements the manoeuvres 
were repeated until 3 technically acceptable readings were obtained, ensuring 
adequate gas washout between each test. 
2.11.5 Exercise inert gas rebreathing protocol 
Following the resting supine and erect measurements described in chapter 
2.11.4 patients then undertook a period of constant load exercise on the upright 
cycle ergometer with measurement of PBF by IGR performed in the final 30 
seconds of exercise. Patients exercised at 40% of the peak work rate achieved 
during baseline cardiopulmonary exercise testing. The IGR test was always 
performed at least one day after the CPET to ensure full recovery from the 
maximal exercise test. After 5 minutes of exercise and while continuing to cycle 
at the same workload the IGR manoeuvre was performed. Due to the difficulties 
of sustaining exercise at that level for a longer period and the need for gas 
washout between tests only one measurement of PBF took place at end-
exercise. 
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2.12 Cardiac magnetic resonance imaging 
Cardiac MRI scanning was performed by specialist radiographers at the Golden 
Jubilee National Hospital, Clydebank, and interpreted by Dr Melanie Brewis, 
Scottish Pulmonary Vascular Unit. All scans were performed on a 1.5T MRI 
scanner (Sonata Magnetom, Siemens Healthcare, Germany) using an established 
protocol191. Fast cine imaging with steady state free precession (SSFP) sequences 
(TrueFISP Siemens) was used for functional imaging. All cine imaging was 
acquired during a 5-8 second breath hold and the total MRI scanning duration 
was approximately 45 minutes per scan. 
Analysis of CMR images was performed using Argus software (Siemens 
Healthcare, Germany). RV and LV volumes were determined by planimetry, 
manually determining the endocardial and epicardial borders of each ventricle 
on each slice of the end diastolic and end systolic images. From this the 
software was able to calculate the RV and LV end diastolic and end systolic 
volumes. Stroke volumes for each ventricle were calculated from the difference 
between the respective ESV and EDV.  Measurements could then be indexed to 
each patient’s body surface area. RV ejection fraction (RVEF) was calculated as 
RV SV / RVEDV * 100. LV ejection fraction (LVEF) was calculated in a similar 
manner with corresponding LV measurements. Flow mapping of the main 
pulmonary artery and aorta was used to provide additional measures of SV from 
the PA and aorta, with and without phase correction. LV SV and aortic SV have 
previously been shown to reflect more accurately than the corresponding right 
sided measurements the SV measured invasively at RHC in patients with PAH192. 
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3 Measurement of mixed venous oxygen 
saturation on exercise in pulmonary 
hypertension  
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3.1 Introduction 
The reduced exercise capacity seen in PH is predominantly a consequence of 
abnormalities in oxygen transport and delivery92 with a lower maximum stroke 
volume93, accelerated heart rate response95 and often a degree of anaemia96 
contributing. It has been postulated that abnormalities in the exercising 
peripheral muscle may also contribute to the reduction in exercise capacity.  
Compared with control subjects the skeletal muscle of patients with PAH has 
been demonstrated to have lower capillarity and an impaired in vitro angiogenic 
response108, 193. This reduced muscle capillarity has been shown to correlate with 
exercise capacity in patients with PAH108. In addition to these changes in the 
muscle microvasculature patients with PH have an alteration in muscle fibre 
type with a relative decrease in type I and increase in type II fibres when 
compared with controls107, 109, and abnormalities in mitochondrial morphology 
and number have also been demonstrated109. These structural changes are 
accompanied by functional abnormalities. An altered metabolic profile with 
differential enzyme expression favouring a more glycolytic metabolism has been 
demonstrated in patients with PAH107 and molecular changes suggestive of a 
switch in signalling toward muscle proteolysis and away from hypertrophy have 
been identified109. Furthermore a reduction in skeletal muscle strength and 
endurance has been identified in these and other studies107-109, 193, 194. Similarly, 
in patients with chronic obstructive pulmonary disease, a respiratory disease 
where the primary abnormality is within the lungs, limb muscle atrophy and 
weakness are well characterised and are known to play a role in exercise 
limitation195. 
Patients with mitochondrial myopathies have been demonstrated to have 
reduced oxygen extraction on exercise, manifesting as abnormally high venous 
oxygen saturation196, 197, lower peak systemic arteriovenous oxygen difference198 
and a smaller increase in deoxygenated haemoglobin and myoglobin during 
exercise199. Given the documented abnormalities of skeletal muscle in patients 
with PAH it is reasonable to consider whether these changes cause a similar 
impairment of oxygen extraction as that seen in patients with myopathies and in 
turn whether this limits exercise capacity in PAH. Evidence in support of this 
comes from a retrospective review of cardiopulmonary exercise tests carried out 
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in patients either undergoing assessment for heart or lung transplantation, or 
presenting with unexplained dyspnoea110. Each CPET was conducted with 
invasive monitoring in the form of radial and pulmonary arterial catheters. The 
study divided subjects into those with PAH, left ventricular systolic dysfunction 
(SD) and left ventricular diastolic dysfunction (DD) and found that those in the 
PAH group had reduced oxygen extraction compared with those in the DD and SD 
groups. However the PAH group included patients with normal resting pulmonary 
artery pressure who developed elevated PAP on exercise and therefore differs 
from the population of patients with resting PAH who suffer the greatest 
morbidity and mortality. 
In this study we performed right heart catheterisation on exercise in patients 
with true resting PAH to evaluate the hypothesis that there is impairment of 
oxygen extraction in the peripheral muscles on exercise in this patient group. 
 
3.2 Methods 
3.2.1 Study subjects 
Patients undergoing baseline diagnostic assessment (see Chapter 1.4) at the 
SPVU were invited to participate in this study. All subjects were treatment naïve 
and were undergoing routine right heart catheterisation as part of their 
diagnostic evaluation. All had performed a maximal CPET two days prior to the 
RHC. Patients were eligible to participate if they were able to give informed 
written consent, had no musculoskeletal or neurological impediment to exercise 
and had resting haemodynamic measurements at RHC compatible with a 
diagnosis of precapillary pulmonary hypertension by standard criteria as 
described in Chapter 1.4.5. All patients received a diagnosis of group 1 or group 
4 PH. This study was descriptive, aiming to explore whether there appeared to 
be a limit to oxygen extraction by demonstrating the absolute level of mixed 
venous oxygen saturation on maximal exercise in this patient group and 
therefore no power calculation was employed.  
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3.2.2 Study design 
Two days prior to exercise RHC patients all performed a maximal symptom-
limited incremental CPET on an upright cycle ergometer as described in Chapter 
2.6. Resting RHC was undertaken as described in Chapter 2.7.1 before 
proceeding to exercise RHC at a constant work rate of 50% the maximum work 
rate achieved in the preceding incremental CPET (see Chapter 2.7.2).  
3.2.3 Ethical approval 
The West of Scotland Research Ethics Committee (Glasgow, United Kingdom) 
approved the study. All subjects gave informed written consent. 
3.3 Results 
19 patients participated in the study of whom 16 produced acceptable results 
which were included in the analysis. Of the 3 patients excluded in the analysis, 
in one the pulmonary arterial catheter position was lost during exercise RHC and 
could not be repositioned within the pulmonary artery prior to cessation of 
exercise; one on review had performed a clearly submaximal incremental CPET 
and the workload selected for exercise RHC was therefore too low; and one 
patient was diagnosed at multidisciplinary team review with PH secondary to 
sarcoidosis and therefore was classified as having group 5 disease and thus no 
longer met the inclusion criteria.  Baseline characteristics of the 16 included 
patients are given in table 3.1. 
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Baseline characteristics 
Diagnosis (n) 
Group 1 
IPAH 
CTDPH 
PPH 
 
Group 4 
 
9 
 
 
 
 
  7 
 
 
6 
1 
2 
 
Gender (n) 
Female 
Male 
 
7 
9 
Age (years) 53 (20) 
WHO FC (n) 
II 
III 
 
9 
7 
6MWD (metres) 386 (103) 
Workload for 
exercise RHC (W) 
40 (13) 
Table 3.1 Baseline characteristics. IPAH: idiopathic pulmonary arterial hypertension; 
CTDPH: connective tissue disease associated pulmonary hypertension; PPH: 
portopulmonary hypertension; WHO FC: functional class; 6MWD: 6 minute walk distance; 
RHC: right heart catheterisation. Data given as number (n) or median (interquartile range). 
 
 
The resting and exercise RHC measurements are described for the whole group 
in table 3.2 and for individual patients in table 3.3. The relative change in 
haemodynamic measurements is demonstrated in figure 3.1. For almost all 
patients the PASP rose to a greater degree than the PADP, leading to an increase 
in pulmonary artery pulse pressure (PApp, the difference between PASP and 
PADP) on exercise. In only one patient did the PApp fall (patient 7 in table 3.3), 
a consequence of a more marked increase in PADP and a relatively more modest 
increase in PASP than seen in the other patients in the group. 
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Resting and exercise right heart catheterisation 
 Resting Exercise 
PASP (mmHg) 80 (18) 114 (37) 
PADP (mmHg) 32 (13) 41 (10) 
mPAP (mmHg) 50 (14) 77 (20) 
PAWP (mmHg) 6 (2) 10 (2) 
CO (l/min) 3.9 (1.3) 5.7 (2.8) 
PVR (Wood units) 11.1 (6.7) 10.8 (4.6) 
HR (beats/min) 74 (21) 126 (17) 
SV (ml) 46 (21) 49 (32) 
SvO2 (%) 62 (8) 22 (11) 
pO2 (kPa) 4.3 (0.3) 2.5 (0.5) 
Table 3.2 Resting and exercise right heart catheterisation. PASP: pulmonary arterial systolic 
pressure; PADP: pulmonary artery diastolic pressure; mPAP: mean pulmonary artery 
pressure; PAWP: pulmonary artery wedge pressure; CO: cardiac output; PVR: pulmonary 
vascular resistance; HR: heart rate; SV: stroke volume; SvO2: mixed venous oxygen 
saturation; pO2: partial pressure of oxygen in mixed venous blood. 
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  Individual haemodynamic responses to exercise 
Patient Age M/F Diag. 
 
Resting 
 
Exercise 
PASP PADP mPAP PAWP CO PVR HR SV PASP PADP mPAP PAWP CO PVR HR SV 
1 71 M IPAH 79 34 50 2 3.8 12.6 94 40 ** ** ** ** 4.8 ** 120 40 
2 43 M CTEPH 58 12 29 5 4.4 5.5 58 76 ** ** ** ** 11.3 ** 135 84 
3 29 F IPAH 94 54 70 5 2.5 26 111 23 ** ** ** ** 3.1 ** 141 22 
4 51 M CTEPH 90 40 63 * 3.2 * 71 45 170 50 100 * 4.6 * ** ** 
5 64 M IPAH 80 29 47 5 3.9 10.8 74 53 145 47 86 22 6.1 12 128 48 
6 55 F CTEPH 101 38 59 7 3.5 14.9 79 44 178 58 100 10 4.1 22 ** ** 
7 71 M CTEPH 66 13 51 7 4.5 5.3 62 73 83 41 63 * 7.6 * 75 101 
8 45 F IPAH 81 33 50 4 2.9 15.9 94 31 110 37 66 6 4.2 14.3 126 33 
 
 
 
 
 
 
 
 
             
 
Table 3.3, continued overleaf 
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  Individual haemodynamic responses to exercise 
Patient Age M/F Diag. 
 
Resting 
 
Exercise 
PASP PADP mPAP PAWP CO PVR HR SV PASP PADP mPAP PAWP CO PVR HR SV 
9 48 M CTEPH 74 30 47 6 3.2 12.8 69 46 113 40 70 9 5.0 12.3 141 35 
10 60 F CTDPH 80 23 43 3 4.3 9.3 74 58 114 32 68 3 6.0 10.8 120 50 
11 76 M CTEPH 74 20 40 6 4.9 6.9 87 56 102 38 66 8 7.5 7.7 125 60 
12 39 M PPH 92 34 55 6 6.4 7.7 83 77 137 45 84 10 9.8 7.6 137 72 
13 47 F PPH 58 23 36 6 2.7 11.1 66 41 98 28 60 9 5.3 9.7 126 42 
14 66 M CTEPH 77 34 55 7 3.2 13.1 73 44 108 52 77 11 6.3 10.6 120 53 
15 56 F IPAH 68 20 37 10 5.9 4.1 62 95 134 33 78 10 11.6 5.9 108 107 
16 45 F IPAH 129 44 75 9 4.2 15.2 108 39 155 47 86 14 4.8 15 140 34 
Table 3.3 Individual haemodynamic responses to exercise. M: male, F: female; Diag: diagnosis; IPAH: idiopathic pulmonary arterial hypertension; CTEPH: 
chronic thromboembolic pulmonary hypertension; CTDPH: connective tissues disease associated pulmonary hypertension; PPH: portopulmonary 
hypertension; PASP: pulmonary artery systolic pressure (mmHg); PADP: pulmonary artery diastolic pressure (mmHg); mPAP: mean pulmonary artery 
pressure (mmHg); PAWP: pulmonary artery wedge pressure (mmHg); CO: cardiac output (l/min); PVR: pulmonary vascular resistance (Wood units); HR: 
heart rate (beats/min); SV: stroke volume (ml). * unable to obtain reliable pressure trace to measure PAWP accurately; ** unrecorded data: peak pressures 
not recorded for patients 1-3; HR (and therefore SV) not recorded for patients 4 and 6. 
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Figure 3.1 Peak exercise haemodynamics as a proportion of their resting values, expressed 
here as the median ratio of peak exercise to resting measurements for all patients. PASP: 
pulmonary arterial systolic pressure; PADP: pulmonary artery diastolic pressure; mPAP: 
mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; CO: cardiac 
output; PVR: pulmonary vascular resistance; HR: heart rate; SV: stroke volume. 
 
Comparing the increase in mPAP with the increase in CO demonstrates a range of 
values as shown in table 3.4, giving a median mPAP-CO slope on exercise of 12 
mmHg/l/min (IQR 9 mmHg/l/min). 
The median mixed venous oxygen saturation (SvO2) fell from 66% at rest to 22% 
at peak exercise. The measurements at rest and at peak exercise for each 
patient are shown in Figure 3.2. Patients with lower resting SvO2 had generally 
lower peak exercise SvO2 (Figure 3.3) although the reduction in SvO2 on exercise 
was greater in patients with higher resting SvO2 (Figure 3.4). 
For patient 6 the blood gas analyser was unable to calculate the oxygen 
saturation from pO2 using its standard equation due to the very low level 
achieved (pO2 = 1.84 kPa) and therefore a separate equation200 was used to 
estimate the SvO2 for this patient to facilitate comparison across the patient 
group as 5 of the 16 patients had only the SvO2 recorded and not the 
corresponding pO2 value. 
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Relative increases of mPAP and CO on exercise 
Patient Δ mPAP Δ CO mPAP-CO slope 
4 37 1.4 26.4 
5 39 2.2 17.7 
6 41 0.6 68.3 
7 12 3.1 3.9 
8 16 1.3 12.3 
9 23 1.8 12.8 
10 25 1.7 14.7 
11 26 2.6 10.0 
12 29 3.4 8.5 
13 24 2.6 9.2 
14 22 3.1 7.1 
15 41 5.7 7.2 
16 11 0.6 18.3 
Table 3.4 Increases of mean pulmonary artery pressure and cardiac output on exercise.       
Δ mPAP: change in mean pulmonary artery pressure on exercise (mmHg); Δ CO: change in 
cardiac output on exercise (l/min); mPAP-CO slope: Δ mPAP / Δ CO (mmHg/l/min). 
 
 
Figure 3.2 Mixed venous oxygen saturation at rest (SvO2 rest) and peak exercise (SvO2 ex) 
for each patient. 
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Figure 3.3 Peak exercise versus resting mixed venous oxygen saturations (SvO2).  
 
 
Figure 3.4 Change on mixed venous oxygen saturation (SvO2) on exercise versus resting 
SvO2. The change in SvO2 is given as the absolute reduction in percentage saturation from 
rest to peak exercise.  
 
To obtain an estimate of the relative oxygen extraction at peak exercise the 
difference between the arterial and mixed venous saturations was expressed as 
a proportion of the arterial saturation at peak exercise. As no systemic arterial 
blood sampling was undertaken as part of this study the peripheral arterial 
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oxygen saturation as measured by pulse oximetry was used. The results are given 
in Table 3.5. 
 
Oxygen extraction at peak exercise 
Patient SaO2 (%) SvO2 (%) (SaO2-SvO2)/SaO2 
4 79 19 0.76 
5 98 16 0.84 
6 93 17 0.82 
7 88 23 0.74 
8 99 25 0.74 
9 95 20 0.79 
10 79 31 0.61 
11 * 31 * 
12 96 37 0.61 
13 * 28 * 
14 79 16 0.80 
15 * 31 * 
16 96 20 0.79 
Table 3.5 Oxygen extraction at peak exercise. Quantification of oxygen extraction at peak 
exercise taken as the difference between arterial oxygen saturation measured by pulse 
oximeter and mixed venous oxygen saturation measured by blood gas analysis, divided by 
the arterial oxygen saturation. SaO2: arterial oxygen saturation; SvO2: mixed venous oxygen 
saturation. * no peak exercise arterial oxygen saturation recorded. 
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3.4 Discussion 
In this study the response to exercise in treatment naïve patients at the point of 
diagnosis with group I and IV pulmonary hypertension was studied at right heart 
catheterisation to determine the haemodynamic response profile and in 
particular to measure the mixed venous oxygen saturation at maximal exercise 
to investigate the hypothesis that there is impairment of peripheral muscle 
oxygen extraction in PH. All patients exhibited a rise in PA pressures and cardiac 
output with an essentially flat stroke volume response. The mPAP-CO slope was 
abnormal in all patients, reflecting the underlying pathophysiology. Mixed 
venous oxygen saturations fell markedly and suggest that there was no 
significant impairment of oxygen extraction limiting exercise capability in the 
studied patients. 
3.4.1 The haemodynamic response 
This study demonstrated a sharp increase in PA pressures on exercise with a 
more modest increase in CO. The relative increases in mPAP and CO are in 
keeping with data published in a study of similarly treatment naïve patients 
newly diagnosed with PAH or distal CTEPH also undergoing supine exercise201 
although the absolute rises in both measurements were less marked than seen in 
the results presented above. That study employed a stepwise incremental 
protocol and the median maximum work rate was lower at 30W compared to 
40W which will have contributed in part to the lower absolute rises seen in their 
work however the patients appear to have had less severe disease with lower 
resting median mPAP (34 mmHg versus 50 mmHg), higher median CO (5.2 l/min 
versus 3.9 l/min, lower median resting PVR (4.6 Wood units versus 11.1 Wood 
units) and higher median 6MWD (445m versus 386m) than in the study presented 
in this chapter. 
The steep mPAP-CO slope is a reflection of the abnormal nature of the 
pulmonary vasculature and its impaired ability to adapt to the stress of exercise. 
Several studies in healthy individuals have demonstrated the normal mPAP-CO 
slope to be less than 3 mmHg/l/min202-205 and this value has been accepted as 
the upper limit of normal111, 113. Resistance is considered the ratio of driving 
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pressure to flow and therefore the standard equation for PVR describes it in 
terms of mPAP, PAWP and CO thus111, 113 
𝑃𝑉𝑅 =
(𝑚𝑃𝐴𝑃 − 𝑃𝐴𝑊𝑃)
𝐶𝑂
 
which can be rewritten for mPAP as 
𝑚𝑃𝐴𝑃 = 𝑃𝑉𝑅 ⋅ 𝐶𝑂 + 𝑃𝐴𝑊𝑃 
In healthy subjects PVR is seen to decrease on exercise and although the fall is 
smaller in supine exercise it still occurs in the normal pulmonary circulation113, 
202. The reduction in PVR is primarily due to the distensibility of the pulmonary 
vasculature and in vitro modelling has demonstrated the profound difference in 
mPAP a small change in distensibility can cause at higher levels of cardiac 
output113 such as might be seen with exercise. This study demonstrates that in a 
group of patients with precapillary pulmonary hypertension there is minimal 
change in PVR in response to exercise and this occurs presumably largely due to 
a pathological loss of pulmonary vascular distensibility although there may be a 
contribution from exercise induced pulmonary vasoconstriction occurring 
secondary to sympathetic nervous system activation and a lower oxygen 
saturation in the returning venous blood206. The inability to reduce sufficiently 
the PVR in response to an increasing CO on exercise is the cause of the steep 
mPAP-CO slope seen in this study and in other groups of patients with PH115, 201, 
207, 208. 
In this study there was no significant change in stroke volume on exercise, 
adding to the evidence describing the stroke volume exercise response in 
patients with precapillary PH. There is a large body of evidence demonstrating 
that in healthy individuals stroke volume increases on exercise in the upright 
position209 but the evidence is mixed when exercise is undertaken supine with 
studies variously describing an increased210, decreased211 or unchanged212, 213 
stroke volume on exercise. Previous imaging studies in PAH have demonstrated a 
stable or falling SV on exercise with one study showing all but one subject with 
IPAH failing to augment SV on exercise93 and a separate study finding a fall in SV 
on exercise116. It is likely that the increased venous return at rest in the supine 
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compared with erect position due to elevation of the legs maximises right 
ventricular filling and, via the Frank-Starling mechanism, stroke volume. Given 
the RV is already under strain in PH due to its increased afterload it is likely that 
as mPAP increases rapidly on exercise the RV struggles to adapt and thus is 
unable to augment SV in the supine position.  
3.4.2 Oxygen extraction on exercise 
This study investigated the extent to which an impairment of peripheral muscle 
oxygen extraction might contribute to the exercise limitation in PH by measuring 
the mixed venous oxygen saturation at end exercise, demonstrating a median 
level of 22%. While those patients achieving the lowest exercise SvO2 tended to 
have the lowest resting SvO2, those patients with a higher resting SvO2 
demonstrated a greater absolute reduction in SvO2 than those with lower resting 
SvO2.  
If there were a significant myopathic type component causing exercise limitation 
then it would be expected that due to the impairment of oxygen extraction the 
mixed venous oxygen level would be higher than in healthy individuals. There 
were no comparator subjects included in this study, either healthy individuals or 
patients with myopathy. While acknowledging the difficulties of comparing 
studies performed with differing exercise protocols it may nevertheless be 
helpful to put the results of this study into context by considering the oxygen 
levels seen in other states of health and disease at maximal exercise as shown in 
Figure 3.5. This would suggest that the current results are not in keeping with a 
myopathic picture and that in patients in this study oxygen was extracted down 
to a similar level to that seen in healthy individuals. 
A further method of considering oxygen extraction is to use the systemic oxygen 
extraction ratio (SER).  
𝑆𝐸𝑅 =
𝐶𝑎 − ?̃?𝑂2
𝐶𝑎𝑂2
 
 where  Ca - ṽO2 is arteriovenous oxygen content difference and 
   CaO2 is arterial oxygen content. 
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Figure 3.5 Peak exercise venous pO2 levels from different studies in health and disease: 
healthy individuals214; after endurance training215; in left heart failure216; in mitochondrial 
myopathy197 and patients from the current study with pulmonary hypertension. 
 
Calculation of SER would have required arterial sampling which was not included 
as part of this study. As a surrogate measure however extraction was estimated 
as (SaO2-SvO2)/SaO2. One study employing SER in healthy individuals undertaking 
leg exercise found a mean SER of approximately 0.7 in this group214. In 
comparison with that value for a normal SER the surrogate measure employed in 
this study and presented in Table 3.5 demonstrated a ratio of greater than 0.7 in 
all but 2 of the patients in whom it could be calculated.  
Together with the comparatively low peak exercise mixed venous oxygen levels 
achieved on exercise, these two elements of the analysis do not support the 
hypothesis that there is a myopathic component to exercise limitation in PH. 
While the abnormalities seen in peripheral muscle are well established107-109, 193, 
194 they do not appear to have had an impact on oxygen extraction in the patient 
group studied. There is a level below which further oxygen extraction is not 
possible, occurring as a combination of a reducing diffusion gradient and 
mitochondrial limit to oxygen uptake and usage217, 218 and the sigmoid shape of 
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the oxyhaemoglobin dissociation curve, with high affinity for oxygen at low 
saturations94. The results of this study would suggest that the exercising 
peripheral muscle is extracting oxygen to a level approaching this limit and that 
the primary limiting factor is therefore the amount of oxygen which is being 
delivered to the muscle, i.e. limitation is central rather than peripheral. It is 
reasonable to consider given the known muscle abnormalities that an increase in 
oxygen delivery to the exercising muscle might “unmask” an impairment of 
oxygen extraction but in this group of treatment naïve patients with true 
pulmonary arterial disease there was no evidence of abnormal extraction 
limiting exercise performance. 
These results are in contrast to those seen in the study by Tolle et al which 
investigated a group of patients who developed PAH on exercise and found a 
reduction in SER110. The significance of patients with normal resting PA pressure 
who develop PH on exercise remains controversial113, 219 and the current 
consensus view is that there is insufficient evidence to define clinically 
significant exercise induced PH2. It may be that the patients in that study had 
early disease and that perhaps the muscle abnormalities manifest earlier than 
the central limitation. It is possible that as the disease process advances the 
progressive pulmonary vascular remodelling and consequent rise in PA pressure 
and onset of RV failure come to predominate and by the time of diagnosis with 
resting PH the central limitation is such that the peripheral muscle abnormalities 
have a minimal influence. Differences in the exercise protocol may also have 
played a role while their methodology has also been questioned220. 
There are limitations to this study. Firstly, there was no comparator group. The 
inclusion of a control group of healthy individuals and a further group of patients 
with mitochondrial myopathy would have allowed a clear comparison between 
their results and the results of the patients with PH. Secondly, the study 
protocol involved sampling of venous blood from the main pulmonary artery and 
thus by the time it was sampled, blood returning from the exercising muscles 
would have mixed with venous blood returning from the rest of the body. In 
order to isolate the exercising muscle and sample blood from just proximal to 
the confluence of the left and right common iliac veins while also taking central 
haemodynamic measurements the insertion of a second venous catheter would 
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have been required. This was not felt to be appropriate. Sampling from the main 
PA will have led to a venous saturation higher than would have been recorded if 
sampling solely the blood draining from the exercising legs and therefore the 
outcome of the study was not affected. Finally, it would ideally have been 
feasible to take muscle biopsy samples at baseline to demonstrate that the 
muscle abnormalities documented by other groups were present in the group 
studied but that they did not affect oxygen extraction. 
 
3.5 Conclusions  
This study has shown no evidence that there is an impairment of oxygen 
extraction in patients with PH which contributes to exercise limitation. Indeed it 
appears that the exercising muscles are extracting oxygen to a similar level seen 
in healthy individuals. The study provides further evidence that the cause of 
exercise limitation in PH is a central impairment of oxygen delivery to the 
muscles rather than a primary myopathic impairment. 
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4 Oxygen uptake efficiency slope in pulmonary 
hypertension  
  89 
 
4.1 Introduction 
Interest in using CPET as part of the assessment and monitoring of patients with 
PH has increased in recent years92, 101. Maximal oxygen uptake is the gold 
standard measure of exercise performance with peak VO2 used as a more 
practical surrogate117, 178. Peak VO2 has been shown to predict survival in PAH125, 
126, 130 but requires patients to perform a maximal exercise test. It is therefore 
dependent on patient motivation221 and although CPET has a good safety record 
in cardiopulmonary disease including PH95, 118, 222, concerns have nevertheless 
been expressed regarding the performance of maximal exercise testing in 
patients with cardiopulmonary disease92, 223. Attention has therefore focused on 
measurements which can be made at submaximal levels of exercise. The most 
commonly studied of these in PH is the relationship between minute ventilation 
and CO2 output with both the slope of that relationship over the course of the 
exercise test100 and the value of the VE/VCO2 ratio at anaerobic threshold129 
being predictive of survival. However these variables are not measures of 
exercise performance. 
Oxygen uptake efficiency slope (OUES) is an index derived from breath by breath 
values of ventilation (VE) and oxygen uptake (VO2) measured over the course of 
an incremental cardiopulmonary exercise test187 (see Chapter 2.8.1). The OUES 
is recognised as describing the combined functional performance of the 
cardiovascular, pulmonary and peripheral skeletal muscle systems during 
exercise221. It was initially developed in a population of young healthy volunteers 
and patients with congenital or acquired cardiac disease (mean age 11.7 years, 
range 5.8 to 29 years)187 and was notable for two key reasons. Firstly, OUES was 
found to correlate strongly with peak VO2 and therefore it could be considered a 
surrogate measure of exercise performance. Secondly, the value of OUES 
determined from the first 90% of maximal exercise tests was not significantly 
different to the OUES value calculated from the full exercise tests. Although the 
value of OUES calculated from the first 75% of tests was on average 3.5% lower, 
OUES determined from both 90% and 75% of tests retained a strong correlation 
with peak VO2. It was therefore suggested that OUES could be used to provide a 
measure of exercise performance from submaximal exercise. This finding was 
replicated in a group of 998 healthy adults in a study which also demonstrated 
less variability in OUES on repeat testing than was seen with peak VO2221. A 
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correlation between OUES calculated from 100% of test data and from tests 
truncated on the basis of respiratory exchange ratio rather than exercise time in 
a further group of healthy volunteers was also shown, particularly at higher 
exercise levels223. 
The role of OUES in the assessment of patients with cardiac disease has been 
investigated in several studies. It has been shown to be correlated with exercise 
capacity in older patients with ischaemic heart disease224, to be reduced in 
patients with left heart failure both with and without a reduced left ventricular 
ejection fraction225, and to correlate significantly with peak VO2 in a similar 
group of patients with cardiac disease regardless of the presence or absence of 
left ventricular impairment226. That study also demonstrated stability of OUES 
measured across the exercise period. A separate study demonstrated that in 
patients with clinical evidence of heart failure peak VO2 was significantly 
affected by changes in lung function whereas OUES was not, suggesting that 
perhaps OUES was isolating the cardiac component of exercise limitation227. 
OUES has also been shown to predict outcome in cardiac disease228. A study of 
cardiopulmonary exercise testing in patients with chronic heart failure 
demonstrated that not only did OUES predict survival on univariate analysis 
alongside peak VO2, VE/VCO2 slope and ventilatory anaerobic threshold but also 
it was the only exercise variable predictive of survival on multivariate 
analysis229. That study also demonstrated little change in OUES when it was 
calculated from only the first 50% of the exercise tests. A further study 
investigating the effect of both OUES and percentage predicted OUES in 
comparison to other exercise derived variables on survival in patients with left 
ventricular failure found that both expressions of OUES were retained in final 
multivariate models although VE/VCO2 slope was the strongest predictor230. 
The studies described in this chapter therefore assessed the potential role of 
OUES in PH, both in terms of assessment of function and as a predictor of 
survival, to investigate the hypotheses that OUES is strongly correlated with 
peak VO2 in PH, that it is valid as a submaximal measure of exercise 
performance in groups I and IV PH and that it predicts survival in patients within 
these disease groups. 
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4.2 Methods 
4.2.1 Comparison of OUES and peak VO2 
To assess the validity of using OUES as a measure of peak exercise performance 
the slope values were compared to the measured peak VO2 for a series of CPETs. 
Only CPETs meeting recognised criteria for a maximal test were included178. All 
patients were treatment naïve at the time of the test and all CPETs were 
conducted within 48 hours of confirmation of pulmonary hypertension at right 
heart catheterisation (Chapter 2.7.1). Patients diagnosed in accordance with 
international guidelines2, 4 with idiopathic pulmonary arterial hypertension 
(IPAH), connective tissue disease associated pulmonary hypertension (CTDPH), 
chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary venous 
hypertension (PVH) were included.   
The value of the OUES was calculated for each subject as described in Chapter 
2.8.1 and plotted against peak VO2. Linear regression analysis was performed to 
describe the relationship between peak VO2 and OUES for each group and tested 
for a statistically significant difference (IBM SPSS Statistics, International 
Business Machines Corp, Armok, New York, USA). 
4.2.2 Calculation and analysis of submaximal oxygen uptake 
efficiency slope 
To assess the validity of OUES as a submaximal measure of exercise 
performance, data from maximal incremental cardiopulmonary exercise tests 
was analysed from patients diagnosed with group I and group IV pulmonary 
hypertension, to calculate OUES as described in Chapter 2.8.2. The breath by 
breath exercise data was then truncated at 90%, 75% and 50% of the incremental 
exercise time and OUES calculated from the onset of loaded cycling to each 
truncated time point. The slope values obtained at each level were plotted 
against OUES calculated from the corresponding full test and the strength of the 
relationship between these was assessed by Pearson correlation (IBM SPSS 
Statistics, International Business Machines Corp, Armok, New York, USA). 
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4.2.3 Oxygen uptake efficiency survival analysis 
Data from all available cardiopulmonary exercise tests performed on treatment 
naïve patients at the time of initial diagnosis with group I and group IV PH and 
who were subsequently commenced on specific pulmonary vasodilator therapy 
was collected and used to calculate the OUES for each patient. Survival analysis 
was then undertaken as outlined in Chapter 2.10. 
For some of the older CPETs the original data tables were not available and 
therefore the breath by breath data for oxygen uptake and minute ventilation 
could not be extracted to calculate OUES directly. The original plots of VO2 and 
VE versus time were however available and graph digitising software was used to 
convert the plots back into numerical data to be used to calculate the OUES as 
described in Chapter 2.8.5. 
4.2.4 Ethical approval 
The studies described in this chapter were discussed with the West of Scotland 
Research Ethics Service who felt that as the core data was collected routinely as 
part of clinical practice in SPVU and that the data was fully anonymised prior to 
analysis, no research ethics approval was required. 
4.3 Results 
4.3.1 Oxygen uptake efficiency slope as a measure of peak 
exercise performance in pulmonary hypertension 
59 patients with groups I, II and IV PH had performed maximal CPETs and 
fulfilled the criteria described in Chapter 4.3.1. Their tests were therefore used 
in the assessment of OUES as a measure of peak exercise performance in PH. The 
group’s baseline demographics, haemodynamic results and peak VO2 and OUES 
are described in Table 4.1. Regression analyses for the prediction of peak VO2 
from OUES for each PH diagnosis group are shown in Figure 4.1 with R squared 
values given in Table 4.2. In addition to the OUES derived from maximal tests 
being a strong predictor of peak VO2 in each group of PH studied, the 
relationship between OUES and peak VO2 was not significantly affected by the 
diagnosis group (p = 0.13).   
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Baseline characteristics 
 IPAH CTDPH CTEPH PVH 
Gender (n) 
Male 
Female 
 
9 
13 
 
3 
4 
 
19 
1 
 
4 
6 
Age (years) 54 (23) 54 (16) 63 (13) 71 (13) 
WHO FC (n) 
II 
III 
IV 
 
13 
8 
1 
 
5 
2 
0 
 
11 
9 
0 
 
3 
7 
0 
6MWD (metres) 356 (79) 300 (87) 410 (122) 346 (134) 
mPAP (mmHg) 50 (17) 41 (6) 39 (11) 34 (12) 
PAWP (mmHg) 7 (5) 6 (6) 8 (4) 21 (7) 
CO (l/min) 3.7 (2.2) 4.3 (2.1) 4.3 (1.5) 5.2 (2.6) 
PVR (Wood units) 10.0 (10.0) 8.3 (4.1) 6.9 (3.9) 3.3 (2.3) 
Peak VO2 (l/min) 0.85 (0.32) 0.57 (0.30) 1.07 (0.40) 0.84 (0.52) 
OUES 0.88 (0.54) 0.66 (0.29) 1.23 (0.40) 1.06 (0.88) 
Table 4.1 Baseline characteristics. IPAH: idiopathic pulmonary arterial hypertension; 
CTDPH: connective tissue disease associated pulmonary hypertension; CTEPH: chronic 
thromboembolic pulmonary hypertension; PVH: pulmonary venous hypertension; WHO FC: 
functional class; 6MWD: 6 minute walk distance; mPAP: mean pulmonary artery pressure; 
PAWP: pulmonary artery wedge pressure; CO: cardiac output; PVR: pulmonary vascular 
resistance; VO2: oxygen uptake; OUES: oxygen uptake efficiency slope. Data given as 
number (n) or median (range). 
 
OUES as a predictor of peak VO2 for different groups of PH 
PH group R squared value p value 
IPAH 0.750 <0.001 
CTDPH 0.613 0.037 
CTEPH 0.887 <0.001 
PVH 0.945 <0.001 
Whole group 0.873 <0.001 
Table 4.2 Oxygen uptake efficiency slope (OUES) as a predictor of peak oxygen uptake (VO2) 
for different groups of PH. PH: pulmonary hypertension; IPAH: idiopathic pulmonary arterial 
hypertension; CTDPH: connective tissue disease associated pulmonary hypertension; 
CTEPH: chronic thromboembolic pulmonary hypertension; PVH: pulmonary venous 
hypertension. 
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Figure 4.1 Relationship between oxygen uptake efficiency slope (OUES) derived from 
complete maximal incremental cardiopulmonary exercise tests and peak oxygen uptake 
(VO2). Solid and broken lines are regression lines for each diagnostic group. PH: pulmonary 
hypertension; Diag_code: diagnosis group; IPAH: idiopathic pulmonary arterial 
hypertension; CTDPH: connective tissue disease associated pulmonary hypertension; 
CTEPH: chronic thromboembolic pulmonary hypertension; PVH: pulmonary venous 
hypertension. 
 
 
4.3.2 Oxygen uptake efficiency slope as a submaximal measure 
of exercise performance in pulmonary hypertension 
CPETs for the patient group described in Chapter 4.4.1, excluding those for 
patients with a diagnosis of PVH, were used to assess the use of OUES as a 
submaximal measure of exercise performance in PH. The correlations between 
OUES calculated from each truncated exercise test level and OUES calculated 
from the full test data are demonstrated in Figure 4.2 together with Bland-
Altman analyses of agreement. 
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ρ = 0.985 
n = 49 
p < 0.001 
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ρ = 0.907 
n = 49 
p < 0.001 
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Figure 4.2 Correlation and Bland-Altman plots for OUES calculated from 100% of maximal 
cardiopulmonary exercise tests and OUES calculated from a), b): 90%; c), d): 75%; and e), f): 
50% of test data. OUES: oxygen uptake efficiency slope, r: Pearson correlation coefficient. 
 
ρ = 0.739 
n = 49 
p < 0.001 
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The ability of OUES calculated from each truncated test level to predict peak 
VO2 and therefore exercise capacity was assessed by linear regression and the 
results presented in Table 4.3. There was a strong predictive relationship for 
OUES calculated from the first 90% and first 75% of test data (R2 = 0.845 and 
0.756 respectively) but this was weaker when OUES was calculated from the first 
50% of test data (R2 = 0.551). 
OUES from submaximal exercise levels as a predictor of peak VO2 
OUES exercise level R squared value p value 
90% 0.845 <0.001 
75% 0.756 <0.001 
50% 0.551 <0.001 
Table 4.3 Oxygen uptake efficiency slope (OUES) calculated from maximal cardiopulmonary 
exercise tests truncated to the first 90%, 75% and 50% of test data as a predictor of peak 
oxygen uptake (VO2).  
 
 
4.3.3 Oxygen uptake efficiency slope as a predictor of survival 
Data from 108 patients with group I and group IV PH was used for the assessment 
of OUES as a predictor of survival (4 with PAH secondary to congenital heart 
disease, 20 with CTDPH, 4 with familial PAH, 1 with HIV associated PAH, 37 with 
IPAH, 5 with portopulmonary hypertension and 37 with CTEPH). Their baseline 
characteristics are given in Table 4.4. The median duration of follow up was 580 
days with a range from 13 to 5942 days. During the follow up period there were 
33 deaths from all causes, 0 patients received a lung transplant, 17 patients 
underwent pulmonary endarterectomy and 3 patients were lost to follow up.  
OUES correlated weakly with other measures of disease severity, namely with 
RAP (ρ = -0.234, p = 0.015), CO (ρ = 0.512, p = <0.001), SvO2 (ρ = 0.47, p = 
<0.001), 6MWD (ρ = 0.263, p = 0.006) and log NTproBNP (ρ = -0.437, p = <0.001). 
It also correlated weakly with age (ρ = -0.192, p = 0.047). 
  
  99 
 
Baseline characteristics 
Gender (n) 
Male 
Female 
 
55 
53 
Age (years) 56 (24) 
WHO FC (n)* 
I 
II 
III 
IV 
 
1 
44 
60 
2 
6MWD (metres) 332 (101) 
mPAP (mmHg) 46 (14) 
PAWP (mmHg) 8 (5) 
CO (l/min) 4.2 (1.8) 
PVR (Wood units) 8.4 (6.3) 
SvO2 (%) 64 (13) 
DLCO (% predicted) 57 (27) 
NTproBNP 807 (2146) 
Peak VO2 (l/min) 0.87 (0.46) 
OUES 0.99 (0.85) 
Table 4.4 Baseline characteristics. WHO FC: functional class; 6MWD: 6 minute walk 
distance; mPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge 
pressure; CO: cardiac output; PVR: pulmonary vascular resistance; SvO2: mixed venous 
oxygen saturation; DLCO: diffusing capacity of the lungs for carbon monoxide; NTproBNP: 
N-terminal pro-brain natriuretic peptide; VO2: oxygen uptake; OUES: oxygen uptake 
efficiency slope. * WHO FC not recorded for one patient. 
 
4.3.3.1 Oxygen uptake efficiency slope Cox proportional hazards analysis 
On Cox proportional hazards analysis OUES, peak VO2, age, percent predicted 
diffusing capacity of the lungs for carbon monoxide (DLCO) and VE/VCO2 at 
anaerobic threshold were all demonstrated to predict all cause mortality (Table 
4.5).   
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Univariate Cox proportional hazards analysis 
Variable Hazard ratio p value 
OUES 0.401 (0.179 – 0.897) 0.026 
Peak VO2 0.259 (0.08 – 0.834) 0.024 
Age 1.047 (1.021 – 1.073) <0.001 
DLCO % predicted 0.967 (0.946 – 0.988) 0.002 
VE/VCO2 at AT 1.036 (1.003 – 1.070) 0.032 
Gender 
Male 
Female (reference) 
 
0.696 (0.348 – 1.393) 
-- 
 
0.306 
-- 
WHO FC 
I/II 
III/IV (reference) 
 
0.438 (0.057 – 3.378) 
-- 
 
0.428 
 
RAP 1.031 (0.96 – 1.106) 0.401 
mPAP 0.992 (0.967 – 1.017) 0.532 
CO 0.810 (0.606 – 1.081) 0.152 
PVR 0.994 (0.933 – 1.059) 0.857 
SvO2 0.972 (0.939 – 1.007) 0.115 
6MWD 0.997 (0.992 – 1.002) 0.205 
logNTproBNP 2.168 (0.957 – 4.915) 0.064 
Table 4.5 Univariate Cox proportional hazards analysis for prediction of all cause mortality. 
Hazard ratios expressed as hazard ratio (95% confidence interval). OUES: oxygen uptake 
efficiency slope; VO2: oxygen uptake; DLCO: diffusing capacity of the lungs for carbon 
monoxide; VE/VCO2 at AT: ventilatory equivalent for carbon dioxide at anaerobic threshold; 
WHO FC: functional class; RAP: right atrial pressure; mPAP: mean pulmonary artery 
pressure; CO: cardiac output; PVR: pulmonary vascular resistance; SvO2: mixed venous 
oxygen saturation; 6MWD: six minute walk distance; logNTproBNP: log transformed N-
terminal pro-brain natriuretic peptide. 
 
On multivariate analysis age was the sole remaining covariate in a model 
including OUES and percent predicted DLCO. Only three covariates were 
included due to the number of events occurring (30) to avoid overfitting (Table 
4.6).   
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Multivariate Cox proportional hazards analysis 
Variable Hazard ratio p value 
Age 1.040 (1.014 – 1.067) 0.002 
OUES 0.513 (0.222 – 1.184) 0.118 
DLCO % predicted 0.999 (0.998 – 1.001) 0.331 
Table 4.6 Multivariate Cox proportional hazards analysis for prediction of all cause 
mortality. Hazard ratios expressed as hazard ratio (95% confidence interval). OUES: oxygen 
uptake efficiency slope; DLCO: diffusing capacity of the lungs for carbon monoxide.  
 
4.3.3.2 Survival by oxygen uptake efficiency slope 
Subjects were stratified by OUES tertiles. Kaplan-Meier analysis was undertaken 
and the results for 3 and 4 year survival are presented in Figure 4.3  
 
 
 
p = 0.04 
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Figure 4.3 Kaplan-Meier survival plots for a) 3 year and b) 4 year survival by OUES tertile in 
the study cohort. Tertile 1 represents the subjects with the lowest tertile values and tertile 3 
the highest tertile values for OUES. 
 
4.4 Discussion 
The potential role of the oxygen uptake efficiency slope in the assessment of 
patients with precapillary pulmonary hypertension was investigated in this series 
of studies. OUES was shown to be a valid measure of exercise performance in 
patients with PH through its strong ability to predict peak VO2. The relationship 
between OUES and peak VO2 was the same across different groups of PH and in 
precapillary PH OUES calculated from submaximal levels of exercise was shown 
to predict peak VO2, thus demonstrating that it may be considered a submaximal 
measure of exercise performance in this patient group. OUES at diagnosis was 
also shown to predict all cause mortality in patients with precapillary PH. 
Taken together these results suggest that OUES has a role in the assessment of 
patients with PH, both as a submaximal measure of exercise performance and as 
a predictor of survival. 
p = 0.047 
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4.4.1 Oxygen uptake efficiency slope and peak exercise 
performance 
The potential role of OUES as a measure of exercise performance stems from its 
ability to predict peak VO2. The study results presented in Chapter 4.4.1 
demonstrates that this relationship is maintained in patients with PH and 
therefore OUES can be considered a surrogate measure of exercise performance 
in such patients. OUES was a strong predictor of peak VO2 in subjects with IPAH, 
CTEPH and PVH (R squared values of 0.75, 0.887 and 0.945 respectively) and 
although the strength of prediction seen was lower in patients with CTDPH (R 
squared value of 0.613) this is likely to reflect the small number of patients in 
this group (7 patients versus 22, 20 and 10 patients for the IPAH, CTEPH and PVH 
groups respectively).  
On exercise the minute ventilation (VE) for a given VCO2 is dependent on the 
arterial partial pressure of CO2 (PaCO2) and the physiological dead space fraction 
(VD/VT) as follows 
𝑉𝐸
𝑉𝐶𝑂2
=
1
𝑃𝑎𝐶𝑂2 (1 −
𝑉𝐷
𝑉𝑇
)
 
Patients with CTEPH have been shown to have a steeper VE/VCO2 slope than 
patients with IPAH, driven by an increase in physiological dead space103. Given 
this increased ventilatory inefficiency or “excess exercise ventilation”102 in 
CTEPH compared with IPAH it might have been expected that the OUES, as the 
relationship between VO2 and log transformed minute ventilation on exercise, 
would have been lower for a given VO2 in the CTEPH group compared with IPAH 
however no significant difference was seen. One possible explanation for this is 
that the number of patients in each group was too small to detect a difference 
and this could be explored by repeating the study in a larger cohort of patients, 
ideally alongside a control group of healthy individuals. 
The potential advantage of OUES over peak VO2 as a measure of exercise 
performance is that studies in healthy individuals and in patients with cardiac 
disease have shown that it can be calculated from submaximal levels of 
exercise187, 221, 223, 226, 231, 232 and therefore can be used as a submaximal measure 
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of exercise performance in such subjects. This study is the first to investigate 
this key aspect of the OUES in pulmonary hypertension. The results presented in 
Chapter 4.4.2 demonstrate that OUES calculated from the first 90% and first 75% 
of maximal cardiopulmonary exercise tests was strongly correlated with OUES 
calculated from the full test data, with strong agreement seen on Bland-Altman 
analyses. There remained a statistically significant correlation between OUES 
calculated from the first 50% of test data and the full test OUES but the strength 
of this correlation was weaker than that seen at the higher exercise test levels. 
Similarly, OUES measured at the 75% and 90% levels was a strong predictor of 
peak VO2 while OUES calculated from the 50% level was weaker. It is therefore 
appropriate to consider OUES valid as a submaximal measure of exercise 
performance in precapillary PH, at least as far as the 75% level.  
One weakness of this study is that it used only exercise time as a percentage of 
the maximal test to delineate the different submaximal exercise levels. Limited 
work has been carried out in healthy individuals using respiratory exchange ratio 
as a secondary criterion in the reporting of OUES223. Further work should explore 
the potential of RER and other markers of exercise intensity to characterise 
better the level of submaximal exercise beyond which OUES can be considered a 
valid measure of exercise performance. 
4.4.2 Oxygen uptake efficiency slope and survival 
The results presented in Chapter 4.4.3 demonstrate that in the studied cohort of 
patients OUES was significant predictor of all cause mortality both on univariate 
Cox proportional hazards analysis and on Kaplan-Meier analyses for three and 
four year survival. OUES did not remain in the model when multivariate analyses 
including age were conducted. Indeed, age was the only remaining variable in 
the models. One previous study in healthy individuals showed age, sex and body 
surface area to be statistically significant predictors of OUES and equations 
taking account of these factors were developed to give reference values for 
OUES233, raising the possibility of using percent predicted OUES as a candidate 
variable. However the subjects in that study were aged 20-60 years and given 
the median age of patients included in the presented survival analysis was 56 
years, extending the reference values to the older patient group studied was not 
felt to be appropriate. One study which developed reference equations for older 
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healthy individuals used treadmill rather than cycle ergometer exercise221 and 
therefore could not be extrapolated to the current patient cohort. A subsequent 
study has also investigated the impact of OUES on survival in a group of patients 
with idiopathic and associated PAH234. That work showed that OUES was a 
significant predictor of poor outcome in the form of death or atrial septostomy 
on multivariate analysis. However, that model did not include age and the age of 
the patient cohort was not stated. 
Interestingly, some variables generally accepted as predictors of survival in PH 
were not seen to be significant predictors in this patient cohort and this could be 
considered a weakness of this study. RAP, CO, SvO2 and logNTproBNP were found 
to be non-significant. However other established predictors, namely peak VO2, 
percent predicted DLCO and VE/VCO2 at anaerobic threshold, were shown to be 
statistically significant predictors of survival in the study and this provides 
reassurance that the significant results for OUES could be replicated in other 
patient cohorts. Investigation of that is a clear next step in the further 
evaluation of OUES in PH. 
 
4.5 Conclusions 
The presented studies are the first to demonstrate that OUES is valid as a 
submaximal measure of exercise performance in precapillary pulmonary 
hypertension. Furthermore they have demonstrated that OUES is a significant 
predictor of survival in this patient group. Take together these results suggest 
that OUES offers potential benefits over the gold standard peak VO2 and these 
should be explored in future work. 
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5 Rates of recovery of heart rate and oxygen 
consumption after incremental exercise and 
survival in pulmonary hypertension 
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5.1 Introduction 
As described in Chapter 4.2 the role of exercise, and in particular CPET, in the 
assessment and risk stratification of patients with PH has been increasing. 
Attention has generally focused on variables derived from and measurements 
made during the active period of exercise, in the case of CPET from the onset of 
loaded cycling to peak exercise. Increasingly in chronic heart failure and other 
cardiovascular diseases the recovery period after exercise is providing insights 
into both the pathophysiology of these diseases and their associated morbidity 
and mortality235. Of greatest interest is the rate of recovery of heart rate (HR) 
following exercise, notable because it reflects the degree of underlying cardiac 
autonomic dysfunction which in turn is associated with morbidity and mortality.  
Recovery of HR following exercise demonstrates an exponential decay pattern 
governed by the balance of changes in sympathetic and parasympathetic 
activity235, 236. Parasympathetic vagal activity has been shown to increase 
gradually in recovery237 with parasympathetic activity predominating in the early 
phase238. One study in sedentary normal individuals measured heart rate 
recovery (HRR) and noradrenaline concentration during recovery from cycle 
ergometer exercise at three different levels of intensity, finding that restoration 
of vagal tone was responsible for the immediate decline in HR in the first minute 
following the cessation of exercise but that from the second minute after 
exercise noradrenaline concentrations, a marker of sympathetic activity, 
declined linearly with heart rate, suggesting that sympathetic withdrawal was 
responsible for this later period of HRR239. Similar results were seen in a group of 
normal subjects in whom sympathetic blockade with propranolol and 
parasympathetic blockade with atropine were used singly and together to 
elucidate the autonomic changes underlying HRR, demonstrating that the 
recovery in the first 30 seconds after exercise was a result of vagal reactivation 
while the recovery at 2 minutes was a consequence of both vagal reactivation 
and sympathetic withdrawal240. 
Lower cardiac vagal activity is associated with increased morbidity241 and all 
cause mortality241, 242. In a study of 605 subjects aged 50-75 years taken from the 
general population, autonomic dysfunction was demonstrated to be associated 
with all cause and cardiovascular mortality, an association which was strongest 
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in those with a history of diabetes mellitus, systemic hypertension or 
cardiovascular disease243. In studies of patients with recent myocardial 
infarction, increased autonomic dysfunction was associated with increased 
mortality244, 245 and, reflecting the underlying pathophysiology, was highest in 
those with inferior myocardial infarction, 3 vessel versus single vessel coronary 
artery disease and episodes of ventricular tachycardia244. In patients with PH, 
sympathetic hyperactivity246 and increased cardiac sympathetic activation247 
have been demonstrated compared with control subjects, and plasma 
noradrenaline concentrations have been shown to correlate with PAP, cardiac 
index (CI) and PVR248. Increased sympathetic nervous system activation in PAH 
has been shown to be associated with disease severity and to predict clinical 
deterioration on multivariate analysis249. 
Given the impact of autonomic dysfunction on morbidity and mortality in health 
and in a range of cardiopulmonary diseases, and that the rate of HRR is governed 
by alterations in the autonomic nervous system, HRR will reflect the degree of 
underlying autonomic dysfunction and may thus be a predictor of morbidity and 
mortality. Analysis of treadmill testing in approximately 3000 subjects from the 
Framingham Heart Study who were free of cardiovascular disease demonstrated 
that those individuals with the fastest HRR had a lower risk of coronary arterial 
and cardiovascular disease than those with slower HRR250. In healthy individuals 
slower HRR has been associated with an increased risk of sudden death251 and 
has been shown to predict all cause252, 253 and cardiovascular253 mortality. In a 
study comparing the HRR in the first 30 seconds after exercise in normal 
volunteers with patients with CHF and with endurance trained athletes, a faster 
decay was seen in the trained group and a slower decay noted in the CHF 
group240. Further studies in patients with CHF demonstrated a significantly 
attenuated HRR in this patient group254 and also that CHF patients with faster 
HRR had significantly better survival255.  
One study compared the exercise response of patients with CHF with those with 
PAH and found that in both groups there was a lower than expected HRR at 1 
minute123. In a small case control study in PAH, cases were noted to have a 
significantly lower absolute reduction in HR at 1 minute after exercise compared 
to controls, despite a significant proportion of patients being on active 
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treatment with pulmonary vasodilator therapy256. A further similar case control 
study comparing patients with PAH, 36% of whom were taking specific pulmonary 
vasodilator therapy, with age and gender matched controls found that HRR was 
significantly slower in patients compared with controls as far as the fifth minute 
after CPET257. 
The pattern of recovery of oxygen consumption after exercise is similar to that 
of heart rate in that there is a rapid early decline followed by a longer, more 
gradual return to resting values258-262. The initial rapid decline represents the 
period during which levels of the phosphagens adenosine triphosphate and 
creatine phosphate are replenished in the exercised muscle(s) and haemoglobin 
and myoglobin are reloaded with oxygen259, 263, 264. Most VO2 recovery research 
has tended to focus on the more prolonged, slower phase of excess postexercise 
oxygen consumption which lasts for periods up to several hours after exercise 
however there is evidence of detectable differences in the rate of early VO2 
decline between groups in health and disease. 
In a comparison of trained versus untrained healthy individuals, VO2 recovery 
after cycle ergometer exercise was faster in the trained group from 30 seconds 
post-exercise onwards265. VO2 recovery in the first 3 minutes after exercise has 
been demonstrated to be slower in severe heart failure compared with healthy 
individuals but not different in groups with less severe CHF266. Two further small 
studies both found evidence of slower early phase VO2 recovery in patients with 
CHF compared with normal subjects267, 268 while a separate larger study assessed 
the time taken for VO2 to fall to 50% of its peak value and showed that this early 
recovery was not only prolonged in CHF compared with healthy volunteers but 
also that it increased with increasing severity of CHF269. One study comparing 
the response to constant work rate cycle ergometer exercise of 9 patients with 
primary pulmonary hypertension, what would be termed IPAH under the current 
classification, with 9 matched normal control subjects, showed significantly 
slower VO2 recovery in patients compared with controls270. 
The study presented in this chapter sought to assess the rates of recovery of 
heart rate and VO2 after incremental CPET in patients with precapillary PH and 
to investigate how these relate to survival, to test the hypothesis that prolonged 
early phase recovery will predict survival in PH. 
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5.2 Methods 
5.2.1 Heart rate recovery 
Data from all available cardiopulmonary exercise tests performed in the SPVU on 
treatment naïve patients at the time of initial diagnosis with group I and group 
IV PH (Chapter 2.7.1) and who were subsequently commenced on specific 
pulmonary vasodilator therapy was collected. Tests which did not include at 
least 2 minutes of recorded recovery data were excluded. CPETs were 
performed as described in Chapter 2.6. None of the patients with PH secondary 
to CHD had had atrial or other cardiac surgery which could have affected their 
HR responses. 
HRR was described at 30 seconds, 60 seconds and 120 seconds from onset of 
recovery, both as the absolute reduction in beats per minute at each time point 
and as the heart rate at each time point as a percentage of the peak value. 
Given HRR was calculated from the values recorded at discrete time points it 
was felt that unlike for calculation of the OUES as described in Chapter 4.3.3, 
only tests with complete data tables should be included and therefore no 
digitising software was used to convert CPET plots back into numerical data 
(Chapter 2.8.5) to determine the HRR, minimising the potential for error in this 
measurement. 
5.2.2 Oxygen consumption recovery 
VO2 recovery was calculated in the same manner as that described for HRR in 
Chapter 5.3.1. 
5.2.3 Heart rate and oxygen consumption recovery survival 
analysis 
Survival analysis was undertaken as described in Chapter 2.10. 
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5.2.4 Ethical approval 
The studies described in this chapter were discussed with the West of Scotland 
Research Ethics Service who felt that as the core data was collected routinely as 
part of clinical practice in SPVU and that the data was fully anonymised prior to 
analysis, no research ethics approval was required. 
5.3 Results 
Data from 87 patients with group I and group IV PH was included in the 
assessment of HRR and VO2 recovery as predictors of survival (3 with PAH 
secondary to congenital heart disease, 13 with CTDPH, 3 with familial PAH, 1 
with HIV associated PAH, 32 with IPAH, 4 with portopulmonary hypertension and 
31 with CTEPH). Their baseline characteristics are given in Table 5.1. 
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Baseline characteristics 
Gender (n) 
Male 
Female 
 
44 
43 
Age (years) 56 (23) 
WHO FC (n)* 
I 
II 
III 
IV 
1 
41 
44 
1 
6MWD (metres) 340 (105) 
mPAP (mmHg) 45 (14) 
PAWP (mmHg) 8 (5) 
CO (l/min) 4.2 (1.9) 
PVR (Wood units) 8.4 (6.7) 
SvO2 (%) 64.5 (12.9) 
DLCO (% predicted) 57 (26) 
NTproBNP 809 (2224) 
Peak HR (1/min) 131 (30) 
Peak VO2 (l/min) 0.88 (0.47) 
Table 5.1 Baseline characteristics. WHO FC: functional class; 6MWD: 6 minute walk 
distance; mPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge 
pressure; CO: cardiac output; PVR: pulmonary vascular resistance; SvO2: mixed venous 
oxygen saturation; DLCO: diffusing capacity of the lungs for carbon monoxide; NTproBNP: 
N-terminal pro-brain natriuretic peptide; HR: heart rate; VO2: oxygen uptake. 
 
The median duration of follow up was 531 days with a range from 13 to 1868 
days (interquartile range 941 days). During the follow up period there were 22 
deaths from all causes, 0 patients received a lung transplant, 14 patients 
underwent pulmonary endarterectomy and 0 patients were lost to follow up.  
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5.3.1 Univariate Cox proportional hazards analysis 
The results of univariate Cox proportional hazards analysis for both heart rate 
and VO2 recovery are given in Table 5.2.  
Recovery univariate Cox proportional hazards analysis 
Variable Hazard ratio p value 
HRR 30 0.953 (0.869 – 1.045) 0.302 
HR 30 (% peak) 1.068 (0.944 – 1.208) 0.297 
HRR 60 0.957 (0.915 – 1.000) 0.048 
HR 60 (% peak) 1.058 (0.998 – 1.121) 0.056 
HRR 120 0.936 (0.893 – 0.981) 0.005 
HR 120 (% peak) 1.101 (1.035 – 1.171) 0.002 
   
VO2R 30 0.098 (0.001 – 16.669) 0.375 
VO2 30 (% peak) 0.995 (0.950 – 1.042) 0.822 
VO2R 60 0.066 (0.004 – 1.032) 0.053 
VO2 60 (% peak) 1.024 (0.997 – 1.052) 0.082 
VO2R 120 0.101 (0.010 – 0.995) 0.05 
VO2 120 (% peak) 1.031 (1.005 – 1.058) 0.021 
Table 5.2 Univariate Cox proportional hazards analysis of heart rate and VO2 recovery after 
CPET for prediction of all cause mortality. Hazard ratios expressed as hazard ratio (95% 
confidence interval). HRR 30, 60, 120: absolute reduction in heart rate at 30 seconds, 60 
seconds and 120 seconds of recovery; HR 30 (% peak), HR 60 (% peak), HR 120 (% peak): 
heart rate at 30 seconds, 60 seconds and 120 seconds of recovery expressed as a 
percentage of the peak heart rate achieved. VO2R 30, 60, 120: absolute reduction in VO2 at 
30 seconds, 60 seconds and 120 seconds of recovery; VO2 30 (% peak), VO2 60 (% peak), 
VO2 120 (% peak): VO2 at 30 seconds, 60 seconds and 120 seconds of recovery expressed 
as a percentage of the peak VO2 achieved.  
 
The absolute reduction in HR at 60 and 120 seconds, and the HR at 120 seconds 
expressed as a percentage of the peak HR, were significant predictors of all 
cause mortality on univariate analysis (p = 0.048, 0.005 and 0.002 respectively). 
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The absolute reduction in VO2 at 120 seconds was seen to predict mortality with 
p = 0.05 while the VO2 at 120 seconds expressed as a percentage of the peak VO2 
was also a significant predictor (p = 0.021).  
The results of univariate Cox proportional hazards analysis for other candidate 
variables in given in Table 5.3. 
Univariate Cox proportional hazards analysis 
Variable Hazard ratio p value 
OUES 0.446 (0.177 – 1.123) 0.087 
Peak VO2 0.240 (0.056 – 1.019) 0.053 
Age 1.041 (1.011 – 1.073) 0.008 
DLCO % predicted 0.990 (0.973 – 1.007) 0.267 
VE/VCO2 at AT 1.010 (0.989 – 1.031) 0.366 
Gender 
Male 
Female (reference) 
 
0.756 (0.323 – 1.770) 
-- 
 
0.520 
-- 
WHO FC 
I/II 
III/IV (reference) 
 
1.027 (0.675 – 1.561) 
-- 
 
0.902 
-- 
RAP 1.010 (0.932 – 1.095) 0.803 
mPAP 0.984 (0.949 – 1.020) 0.378 
CO 0.843 (0.624 – 1.139) 0.266 
PVR 0.978 (0.910 – 1.051) 0.543 
SvO2 0.991 (0.969 – 1.014) 0.461 
6MWD 0.996 (0.991 – 1.002) 0.166 
logNTproBNP 2.151 (0.952 – 4.860) 0.065 
Table 5.3 Univariate Cox proportional hazards analysis for prediction of all cause mortality 
by non recovery candidate variables. Hazard ratios expressed as hazard ratio (95% 
confidence interval). OUES: oxygen uptake efficiency slope; VO2: oxygen uptake; DLCO: 
diffusing capacity of the lungs for carbon monoxide; VE/VCO2 at AT: ventilatory equivalent 
for carbon dioxide at anaerobic threshold; WHO FC: functional class; RAP: right atrial 
pressure; mPAP: mean pulmonary artery pressure; CO: cardiac output; PVR: pulmonary 
vascular resistance; SvO2: mixed venous oxygen saturation; 6MWD: six minute walk 
distance; logNTproBNP: log transformed N-terminal pro-brain natriuretic peptide. 
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5.3.2 Multivariate Cox proportional hazards analysis 
On multivariate analysis the absolute reduction in heart rate at 120 seconds was 
the sole remaining covariate in a model including age and logNTproBNP (hazard 
ratio 0.918, 95% confidence interval 0.870 – 0.970, p = 0.002). Similar results 
were seen when HRR was expressed as the heart rate at 120 seconds as a 
percentage of the peak HR (hazard ratio 1.115, 95% confidence interval 1.041 – 
1.194, p = 0.002). However HRR at earlier time points and VO2 recovery at all 
time points were not significant predictors of mortality on multivariate analysis.  
5.3.3 Kaplan Meier analysis of heart rate and VO2 recovery 
Subjects were stratified by tertiles of HR and VO2 recovery. Kaplan-Meier 
analysis was performed for 3 and 4 year survival. The significant results are 
given in Figure 5.1.  
 
p = 0.043 
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Figure 5.1 Kaplan-Meier plots for a) 3 year and b) 4 year survival by tertile of percentage 
peak heart rate at 120 seconds recovery and c) 4 year survival by tertile of absolute heart 
rate recovery at 120 seconds. HRR: heart rate recovery. 
p = 0.043 
p = 0.033 
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5.4 Discussion 
These studies explored the rates of recovery of heart rate and VO2 in the first 
two minutes of recovery after incremental CPET to test the hypothesis that 
prolonged recovery would be associated with an increase in all cause mortality. 
The results demonstrate that the absolute reduction in HR at both 60 seconds 
and 120 seconds of recovery and the HR at 120 seconds expressed as a 
percentage of the peak HR were all significant predictors of mortality on 
univariate analysis, with slower HRR associated with an increased risk of death in 
the patient cohort studied. On multivariate analysis the absolute reduction in HR 
at 120 seconds remained a significant predictor of all cause mortality after 
controlling for age and logNTproBNP.  
These results add to the small body of emerging evidence linking delayed HRR 
with poor outcome in patients with PAH and is the first to do so in treatment 
naïve patients. One study employed a composite endpoint of clinical worsening, 
defined as any one of escalation of PH drug therapy, admission to hospital due to 
PH, lung transplantation or death, and studied the HRR at 60 seconds after 
6MWT271. In contrast to the treatment naïve patient cohort used in the recovery 
analysis presented in this chapter, all but 4 of the 75 subjects in that study were 
on treatment with specific pulmonary vasodilator therapy, including 47 receiving 
parenteral prostanoid therapy, either alone or in combination with oral 
treatment. The authors demonstrated that an absolute fall in HR of less than 16 
beats per minute at 60 seconds of recovery was associated with a higher 
likelihood of clinical worsening events and a shorter time to clinical worsening.  
The same group conducted a similar study of HRR after 6MWT in a cohort of 
patients with CTDPH and again found that an absolute reduction in HR of less 
than 16 beats per minute at 60 seconds of recovery was the strongest predictor 
of hospitalisation, death and time to clinical worsening272. A separate study in a 
cohort of 72 patients with PAH, 26 of whom were on treatment with pulmonary 
vasodilator therapy, found that an absolute reduction in HR of 18 beats per 
minute or less after the first 60 seconds of recovery was associated with poorer 
survival257. 
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In contrast to the results presented in this chapter which showed that HRR at 
120 seconds was a stronger predictor of mortality than HRR at 60 seconds, in the 
study of recovery after 6MWT in patients with CTDPH the HRR at 60 seconds was 
a better predictor than that seen at 120 seconds272. One possible explanation for 
this is that in that study the recovery was passive with the participants sitting at 
rest for the duration of recovery whereas in the presented work patients 
continued cycling at a reduced work rate for at least part of the recorded 
recovery period, providing an ongoing stimulus to subjects to maintain an 
elevated heart rate in the initial recovery period regardless of underlying disease 
severity. It has been shown that HRR is slower in active recovery compared to 
assisted recovery in which the subjects’ legs are moved by an assistant273 and 
that furthermore it is slower in assisted recovery than passive recovery, albeit 
over a timescale of several minutes274. These results have been taken as 
suggesting that the rate of the early phase of HRR is affected both by cessation 
of central drive and by feedback from mechanoreceptors in the exercising 
muscle.  
One weakness of the presented study is that no fixed work rate or duration of 
active recovery was set as part of the CPET protocol. It may be considered that 
patients with more severe disease might cease cycling earlier in recovery, 
leading to a faster rate of recovery and therefore to a potential source of 
systematic bias. That would be expected to reduce the difference between 
patients with more and less severe disease however despite that possible 
influence, in this study slower rates of recovery were still found to be significant 
predictors of survival. 
The study of VO2 recovery after exercise presented in this chapter is the first in 
PAH to study early phase VO2 recovery and its relationship to survival. While 
slower rates of VO2 recovery were associated with increased mortality when 
assessed at 120 seconds after exercise, VO2 recovery was not as strong a 
predictor as HRR and was not a significant predictor of mortality on multivariate 
analysis.  
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6 The use of inert gas rebreathing to measure 
early treatment response in pulmonary 
hypertension 
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6.1 Introduction 
As described in Chapter 1.1 PH is a disease defined by its haemodynamic 
abnormalities and while invasive RHC is required to make the initial diagnosis, 
most ongoing assessment of disease severity and treatment response is made by 
noninvasive surrogate measures such as 6MWD and NTproBNP. Exercise limitation 
is one of the most common features of PH and a large component of this 
limitation is attributable to a failure to augment SV on exercise93, 94, 116, 119. In 
considering the assessment of treatment response it would therefore be of value 
to measure the underlying haemodynamic change but serial measurements with 
RHC are unattractive due to the invasive nature of the test and associated 
potential for complications53.  
Cardiac MRI provides information on the structure and function of the right heart 
and the pulmonary circulation, and has been demonstrated to provide evidence 
of response to treatment. Relief of PH by either PEA or lung transplantation is 
associated with improvements in RV function and PBF275-277. The more subtle 
improvements seen with drug treatment can also be detected with cardiac MRI 
with improvements in RV SV, RV mass (RVM), RVEF and CI seen in a selection of 
trials of oral and intravenous pulmonary vasodilator therapy163, 278-280. However 
this improvement in cardiac MRI variables has not been universally seen with two 
studies of ERAs finding no benefit on either RVEF or RV volumes in response to 
treatment281, 282. 
With exercise limitation one of the key symptoms of PH it is important to 
consider how the underlying haemodynamic abnormalities change on exercise. 
While cardiac MRI has been used to assess changes on exercise the narrow bore 
of an MRI scanner makes exercise while scanning difficult to achieve and studies 
have tended to involve a period of exercise followed by movement into the MRI 
scanner for measurements to take place, thus not achieving the goal of assessing 
patients during exercise93, 283.  
Inert gas rebreathing (IGR) has been shown to allow noninvasive measurement of 
SV on exercise in both chronic heart failure and PH150, 175, 176, 284. In addition it 
has been demonstrated that in patients with Group 1 and Group 4 PH IGR can 
detect changes in SV in response to institution of treatment both at rest and on 
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exercise150. Patients underwent measurement of PBF and SV by IGR at rest in the 
supine and erect positions, and on erect exercise at 40% of the peak work rate 
(WR) achieved on a prior CPET, and in all 3 positions there was an increase in SV 
seen 3 months after commencing treatment. There was a trend to increase in 
6MWD but changes in WHO-FC, NTproBNP and CAMPHOR quality of life 
assessment were not seen. Interestingly that study suggested that measurements 
made by IGR may be more sensitive than 6MWD in detecting treatment change in 
patients with a higher baseline 6MWD. 
It is standard clinical practice to assess the impact of institution or alteration of 
specific pulmonary vasodilator therapy after 3-4 months, primarily by measures 
of function such as 6MWT, CPET and WHO-FC4. However it has been 
demonstrated that acute haemodynamic changes occur in response to treatment 
with each class of disease targeted therapy used in PH: PDE5 inhibitors285-288, 
ERAs289 and prostacyclin analogues81, 207, 287, 288, 290. It is not known if this early 
haemodynamic change predicts clinical response at 3-4 months. If such a 
relationship exists it may be possible to assess patients haemodynamically 
shortly after commencing disease targeted therapy and alter therapy at that 
point if a poor clinical response is predicted. 
This study therefore aimed to explore the feasibility of using IGR to assess the 
early haemodynamic change and explore how it relates to later functional 
improvement to investigate the hypotheses that haemodynamic improvement is 
detectable by IGR, that it is seen earlier that functional improvement and that 
this earlier response is predictive of later change in exercise capacity. 
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6.2 Methods 
6.2.1 Patient recruitment 
Potential subjects were identified by the clinical team at the SPVU with the 
following inclusion and exclusion criteria.  
6.2.1.1 Inclusion criteria 
Subjects with Group 1 or Group 4 PH 
Newly diagnosed patients being commenced on therapy de novo or patients 
already established on pulmonary vasodilator therapy undergoing a change in 
treatment as planned when undergoing routine review in the outpatient clinic. 
6.2.1.2 Exclusion criteria 
Subjects who were unable to perform the 6MWT due to comorbid neurological or 
musculoskeletal limitation 
Subjects with exercise-induced syncope, chest pain or cardiac arrhythmia 
Subjects who were pregnant 
Subjects who were unable to give informed consent 
Subjects who were unable to undergo MRI scanning 
6.2.2 Power calculation 
The study was powered to show a significant change in 6MWD at 4 months. On 
the basis of α of 0.05 and power of 0.8, the required sample size was calculated. 
The effect size of change in 6MWD was taken as 22 metres with a standard 
deviation of the change of 28 metres150. The required sample size was 13. 
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6.2.3 Study protocol 
Subjects were assessed at baseline and at 2 weeks, 4 months and 1 year after 
starting or changing disease targeted therapy. Each assessment involved two 
visits and, except for the 2 week assessment, coincided with routine clinical 
review. Visit 2 occurred 1 day after Visit 1 at all four assessments. At each time 
point the subjects underwent the assessment outlined in Figure 6.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All study procedures were performed as described in Chapter 2.  
Visit 1 
 
 Incremental cardiopulmonary exercise test 
 Cardiac MRI 
 NTproBNP blood assay* 
 CAMPHOR PH quality of life questionnaire 
 WHO functional class assessment 
Visit 2 
 
 Stroke volume measurement by IGR 
 6 minute walk test 
Figure 6.1 Protocol for assessment at each timepoint, baseline, 2 weeks, 4 months and 1 
year. MRI: magnetic resonance imaging, NTproBNP: N terminal pro-brain natriuretic 
peptide: CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review; PH: pulmonary 
hypertension; WHO: World Health Organisation; IGR: inert gas rebreathing. *NTproBNP 
performed at baseline, 4 months and 1 year only. 
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6.2.4 Ethical approval 
Ethical approval for this study was granted by the West of Scotland research 
Ethics Committee. 
6.2.5 Analysis of results 
This study was largely exploratory to assess the feasibility of using IGR to detect 
changes in SV at 2 weeks and if present, to assess their relationship to later 
functional improvement. As described in Chapter 6.3 recruitment to this study 
was lower than expected, thus limiting the statistical analysis given the small 
number of subjects. Significance tests have therefore not been performed. 
 
6.3 Results 
A total of 8 patients were recruited to this study, short of the original 
recruitment target of 13 patients.  
The baseline characteristics for the 8 subjects are given in Table 6.1. The RHC 
data for 6 patients is from RHCs undertaken within a fortnight of study entry, 5 
of whom were at the point of diagnosis and one was undergoing invasive 
reassessment prior to treatment escalation. For one patient the RHC data was 
from 4 months earlier when the diagnosis was made and treatment first 
instituted. For another patient the RHC had last been performed as a child and 
therefore was not included in the figures used for Table 6.1. 
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Baseline characteristics 
Diagnosis (n) 
IPAH 
CTDPH 
CTEPH 
 
4 
3 
1 
Age (years) 54 (14) 
Gender 
Male 
Female 
 
4 
4 
WHO-FC 
I 
II 
III 
 
1 
5 
2 
mPAP (mmHg) 47 (5) 
PAWP (mmHg) 6 (6) 
CO at last RHC (l/min) 4.3 (0.4) 
SV at last RHC (ml) 50 (12) 
PVR at last RHC (Wood units) 9.3 (2.2) 
Table 6.1 Baseline characteristics of participants in early treatment response study. IPAH: 
idiopathic pulmonary arterial hypertension; CTDPH: connective tissue disease associated 
pulmonary hypertension; CTEPH: chronic thromboembolic pulmonary hypertension; WHO-
FC: WHO functional class; mPAP: mean pulmonary artery pressure; PAWP: pulmonary 
artery wedge pressure; CO: cardiac output; RHC: right heart catheterisation; SV: stroke 
volume; PVR: pulmonary vascular resistance. 
 
Absolute values of resting supine SV measured by cardiac MRI and IGR are given 
in Figure 6.2 and Figure 6.3. The comparison of the changes seen in supine SV at 
2 weeks when measured by both IGR and cardiac MRI is given in Figure 6.4. The 
aortic SV measured at MRI was used for the comparison. The direction and 
magnitude of change in SV was similar by both methods for all but one patient in 
whom the mean supine SV increased by 2ml measured by IGR but fell by 7ml 
measured by cardiac MRI. These results suggest that both IGR and cardiac MRI 
area able to detect early haemodynamic changes. 
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Figure 6.2 Absolute values of supine resting stroke volume measured by cardiac MRI (aortic 
SV) and inert gas rebreathing at baseline. SV: stroke volume (ml); MRI: magnetic resonance 
imaging; IGR: inert gas rebreathing. 
 
 
 
Figure 6.3 Absolute values of supine resting stroke volume measured by cardiac MRI (aortic 
SV) and inert gas rebreathing at 2 weeks. SV: stroke volume (ml); MRI: magnetic resonance 
imaging; IGR: inert gas rebreathing. 
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Figure 6.4 Comparison of change in supine stroke volume at 2 weeks as measured by 
cardiac MRI (aortic SV) and IGR. SV: stroke volume (ml); MRI: magnetic resonance imaging; 
IGR: inert gas rebreathing. 
 
The changes in SV by IGR in the supine and erect positions at 2 weeks are given 
in Figure 6.5. The direction of change in SV was the same for all patients 
whether measured supine or erect but the magnitude of the change for some 
patients appeared to be lower with the erect measurements suggesting that 
perhaps the erect measurement may be less responsive to treatment change. 
The relationship between the change in supine SV at 2 weeks and the change in 
6MWD at 2 weeks is given in Figure 6.6. It appears to show a positive relationship 
between the change in SV and the change in 6MWD with those patients with the 
largest increase in SV at 2 weeks also having the largest increase in 6MWD at 2 
weeks. 
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Figure 6.5 Relationship between the change in stroke volume measured by inert gas 
rebreathing at 2 weeks in the supine and erect positions. SV: stroke volume; IGR: inert gas 
rebreathing. 
 
 
Figure 6.6 Relationship between the change in supine stroke volume measured by inert gas 
rebreathing at 2 weeks and the change in 6 minute walk distance at 2 weeks. SV: stroke 
volume (ml); IGR: inert gas rebreathing; 6MWD: 6 minute walk distance (metres). 
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A less clear relationship is seen between by the change in supine SV by IGR at 2 
weeks and the change in 6MWD at 4 months as demonstrated in Figure 6.7. 
 
Figure 6.7 Relationship between the change in supine stroke volume measured by inert gas 
rebreathing at 2 weeks and the change in 6 minute walk distance at 4 months. SV: stroke 
volume (ml); IGR: inert gas rebreathing; 6MWD: 6 minute walk distance (metres). 
 
 
Similarly no clear relationship is seen between the change in supine SV by IGR at 
4 months and the change in 6MWD at 4 months as demonstrated in Figure 6.8. 
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Figure 6.8 Relationship between the change in supine stroke volume measured by inert gas 
rebreathing at 4 months and the change in 6 minute walk distance at 4 months. SV: stroke 
volume (ml); IGR: inert gas rebreathing; 6MWD: 6 minute walk distance (metres). 
 
 
6.4 Discussion 
Although a large volume of data was collected as part of this study, given the 
smaller than expected number of participants it was decided to concentrate on 
the main focus of the study, i.e. if haemodynamic changes can be detected at 2 
weeks after starting or altering disease targeted pulmonary vasodilator therapy 
and whether these changes relate to changes in function at the standard follow 
up time of 4 months.  
SV measured by IGR appears to be able to detect haemodynamic changes 2 
weeks after starting or altering treatment and these changes appear comparable 
to those seen by cardiac MRI. On the basis of the data obtained this change in 
supine SV measured by IGR relates to the change in 6MWD at the same time 
point. Interestingly however the change in 6MWD at 4 months does not appear to 
relate to the change in SV either at 2 weeks or at 4 months. Given the close 
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relationship between impaired stroke volume and exercise limitation it is 
perhaps surprising that the changes seen in 6MWD at 4 months do not appear to 
relate to changes in SV. It is possible however that this is a consequence of the 
small number of patients included in the study. 
The main weakness of this study is the small number of patients who 
participated. Difficulties encountered recruiting to the trial centred on two main 
issues. Firstly, the study protocol was relatively intense with repeated exercise 
testing occurring alongside the other investigations over two visits at each time 
point. Given the large geographical spread of patients attending the SPVU for 
assessment the protocol necessitated an overnight stay for the majority of 
patients and while this could be offered without charge it added to the 
perceived intensity of the visits. Secondly, the recruitment from prevalent 
patients undergoing a change of treatment after assessment in the outpatient 
clinic was less than anticipated. This again stemmed partly from the intensity of 
the study protocol and that in addition to their current clinic review they would 
need to return for a further four days of assessment over a two week period. 
 
6.5 Conclusions 
The limited data from this study appears to show that both IGR and cardiac MRI, 
noninvasive surrogate measures of the underlying haemodynamics, can detect 
changes as early as 2 weeks after a change in treatment. These changes seem to 
relate to changes in 6MWD seen at the 2 week time point but there does not 
appear to be any relationship between the SV changes and the changes observed 
in 6MWD at 4 months. This study was small and further assessment of the role of 
IGR and cardiac MRI in assessing early haemodynamic change and the 
relationship between that and future functional change should be assessed in a 
larger study with a more streamlined protocol to enhance recruitment and lend 
more certainty to these provisional results. 
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7 Major findings and conclusions 
The work in this thesis was undertaken to investigate the extent to which novel 
exercise derived variables and noninvasive haemodynamic measurements can 
enhance the assessment and monitoring of patients with pulmonary 
hypertension.  
Right heart catheterisation on exercise in patients with resting Group 1 and 
Group 4 PH was carried out to test the hypothesis that there is impairment of 
oxygen extraction in the peripheral muscles on exercise in these patient groups. 
The major findings were: 
 On exercise patients with PAH can achieve very low levels of mixed 
venous oxygen saturation, lower than has been previously suggested 
 Oxygen extraction does not appear to be reduced in patients with PH and 
may be higher than in healthy individuals 
 Impairment of oxygen extraction does not appear to be a limiting factor in 
the exercise capacity of patients with PH. 
 
The potential role of the oxygen uptake efficiency slope in the assessment and 
monitoring of patients with PH was investigated. The major findings were: 
 The relationship between OUES and peak VO2 is constant across different 
groups of PH 
 OUES calculated from submaximal levels predicts peak VO2 and therefore 
OUES can be considered a submaximal measure of exercise performance 
in PH 
 OUES is a significant predictor of survival in patients with Group 1 and 
Group 4 PH 
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The rates of recovery of heart rate and VO2 after incremental CPET were studied 
to investigate their relationship with survival in patients with Group 1 and Group 
4 PH. The major findings were: 
 The absolute reduction in HR at 60 and 120 seconds, and the HR at 120 
seconds expressed as a percentage of the peak HR, were significant 
predictors of all cause mortality on univariate analysis 
 The absolute reduction in heart rate at 120 seconds was the sole 
remaining covariate on multivariate analysis in a model including age and 
logNTproBNP. Similar results were seen when the HR at 120 seconds was 
expressed as a percentage of the peak HR 
 The absolute reduction in peak VO2 at 120 seconds and the VO2 at 120 
seconds expressed as a percentage of the peak VO2 were both significant 
predictors of survival on univariate analysis 
 
The ability of noninvasive measurement of stroke volume by inert gas 
rebreathing and by cardiac MRI to detect early haemodynamic changes and the 
relationship of these changes to later functional improvement was investigated. 
The study did not meet its recruitment target but did appear to show on the 
basis of the limited data: 
 Both IGR and cardiac MRI are able to detect haemodynamic changes 2 
weeks after starting or altering pulmonary vasodilator therapy 
 The change in SV at 2 weeks as measured supine by IGR appears to relate 
to changes in 6MWD seen at 2 weeks 
 The change in SV at 2 weeks does not appear to relate to the change in 
6MWD seen at 4 months and similarly the change in SV at 4 months does 
not appear to relate to the change in 6MWD at 4 months 
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In conclusion, the aims of this thesis, to investigate the role of novel exercise 
derived variables and noninvasive haemodynamic measurements in enhancing 
the assessment and monitoring of patients with PH has been achieved. The work 
on oxygen extraction has suggested that while pathological changes do occur in 
the muscles of patients with PH, these do not seem to cause impairment of 
oxygen extraction and consequent exercise limitation. This could be explored 
further through a rehabilitation trial involving exercise right heart 
catheterisation, muscle biopsies and cardiopulmonary exercise testing both 
before and after a course of rehabilitation to clarify in more detail the impact of 
the peripheral muscle abnormalities.  
OUES has demonstrated promise as a submaximal measure of exercise 
performance and predictor of survival in PH and further work on this measure 
and its role in assessing treatment response with serial measurements should be 
explored.  
The rates of heart rate and VO2 recovery after CPET have been shown to predict 
survival. In particular the rate of recovery of HR at 120 seconds after exercise 
has been demonstrated to be a powerful predictor of survival. Work investigating 
how this might combine with other exercise derived and haemodynamic 
variables may lead to enhanced prediction of patient outcome.  
Finally inert gas rebreathing and cardiac MRI both appear able to detect a 
haemodynamic response 2 weeks after treatment. The number of participants 
was too small to draw conclusions on how this change may or may not relate to 
later functional improvement. A larger more streamlined study focusing on this 
issue in isolation may yield interesting results which could change the current 
strategy for assessing treatment response in PH. 
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Appendix 1 CAMPHOR 
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Please read this carefully 
 
 
On the following pages you will find some statements that  
have been made by people who have Pulmonary Arterial Hypertension. 
 
Please read each statement carefully.   
We would like you to put a tick in the box  next to ‘Yes’  
if you feel it applies to you and a tick in the  
box  next to ‘No’ if it does not 
 
Please choose the response that applies best to you 
at the moment 
 
 
© Galen Research & Papworth Hospital, 2004 
 
CAMPHOR 
 
Cambridge Pulmonary Hypertension 
Outcome Review 
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Symptoms 
 
 Please read each statement carefully and decide whether it applies to you  
at the moment  
   
1.   My stamina levels are low   
Yes  
No  
 
  
2.   I have to rest during the day   
Yes  
No  
 
  
3.   I feel worn out 
Yes  
No  
   
4.   I get tired very quickly 
Yes  
No  
   
5.   I’m tired all the time 
Yes  
No  
 
  
6.   I feel very weak 
Yes  
No  
   
7.   I feel completely exhausted    Yes  
No  
   
8.   I want to sit down all the time Yes  
No  
 
  
9.   I soon run out of energy Yes  
No  
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10.   Everything is an effort 
Yes  
No  
   
11.   I get out of breath when I stand up 
Yes  
No  
 
  
12.   When I talk I get out of breath 
Yes  
No  
   
 
Please read each statement carefully and decide whether it applies to you  
at the moment 
 
   
13.   When I walk I get out of breath 
Yes  
No  
 
  
14.   I get breathless if I bend 
Yes  
No  
 
  
15.   I get breathless going up one step 
Yes  
No  
   
16.   I get breathless walking up a slight slope 
Yes  
No  
 
  
17.   I get breathless without doing anything 
Yes  
No  
 
  
18.   I get breathless climbing a flight of stairs 
Yes  
No  
 
 
  
19.   I have mood swings 
Yes  
No  
 
  
20.   I get very down Yes  
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No  
 
  
21.   I seldom feel happy 
Yes  
No  
   
 
 Please read each statement carefully and decide whether it applies to you  
at the moment  
 
   
22.   I’ve forgotten what it’s like to enjoy myself 
Yes  
No  
 
  
23.   I feel hopeless 
Yes  
No  
 
  
24.   It does get me down 
Yes  
No  
 
  
25.   I often feel anxious 
Yes  
No  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
please turn over 
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Activities 
 
Please put a tick in the box  under the response which best describes 
your abilities at the moment.  Please respond to all 15 statements. 
 
Please describe your ability without the use of aids or assistance.  
However, do describe your ability taking into account oxygen if you use 
it. 
 
 
Please mark only one box. 
 
Able to do 
on own 
without 
difficulty 
Able to do 
on own 
with 
difficulty 
Unable to 
do on own 
 
1.   Cut your toenails    
2.   Have an all over wash    
3.   Get dressed    
4. Walk around inside the house (not including 
climbing stairs) 
   
5.   Walk short distances on level ground    
6.   Walk longer distances on level ground    
7.   Walk up a slight incline    
8.   Climb a flight of stairs    
9.   Bend down to pick objects up from the floor    
10.   Stand for a short time    
11.   Stand for a long time    
12.   Lift heavy items    
13.   Carry heavy items    
14.   Do light jobs around the house or garden     
15.   Do heavy jobs around the house or garden    
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Quality of Life 
 
Please read each statement carefully and put a tick  next to the response 
that applies best to you  at the moment  
   
1.    I have to talk very quietly 
True 
Not True 
 
 
   
2.    I can't stay away from home 
True 
Not True 
 
 
   
3.  I've lost interest in food   
True 
Not True 
 
 
   
4.  I can't put energy into my close relationships 
True 
Not True 
 
 
   
5.  Walking for pleasure is out of the question     
True 
Not True 
 
 
   
6.  My condition puts a strain on my close relationships     
True 
Not True 
 
 
   
7.  I feel very isolated     
True 
Not True 
 
 
   
8.  I can’t do things on the spur of the moment      
True 
Not True 
 
 
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9.  I feel vulnerable when  I’m on my own     
True 
Not True 
 
 
 
   
10. It feels like my body has let me down     
True 
Not True 
 
 
   
11.  I feel as if I’m not in control of my life     
True 
Not True 
 
 
   
12. I feel dependent on other people     
True 
Not True 
 
 
   
Please remember to put a tick in only one of the alternative responses for 
each of the statements 
   
13. .Sometimes it’s too much effort to speak      
True 
Not True 
 
 
   
14. I feel as if I am a burden to people     
True 
Not True 
 
 
   
15.  Travelling distances is a problem       
True 
Not True 
 
 
   
16.    I don't like to be seen like this 
True 
Not True 
 
 
   
17.    I feel that I'm losing my role in life 
True 
Not True 
 
 
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18.    I worry that I neglect people close to me 
True 
Not True 
 
 
   
 
Please read each statement carefully and decide whether it applies to you  
at the moment 
   
19.    I feel guilty asking for help 
True 
Not True 
 
 
   
20.  My condition limits the places I can go     
True 
Not True 
 
 
   
21.    I dislike having to rely on other people    
True 
Not True 
 
 
   
22.  I don’t want to talk to anybody    
True 
Not True 
 
 
   
23. I feel as if I let people down     
True 
Not True 
 
 
   
24.  I am reluctant to leave the house 
True 
Not True 
 
 
   
25.   I’m unable to join in activities with my family and friends 
 
True 
Not True 
 
 
 
 
Thank you for taking the trouble to fill in this questionnaire. 
  
Please check all the pages to make sure that you have 
answered every stat__________  
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